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G protein coupled receptors (GPCR) are sensory proteins that transduce a wide range of 
extracellular stimuli including drugs, neurotransmitters, and hormones into diverse physiological 
responses by activating intracellular effectors (G proteins or arrestins). Dysfunction in GPCR 
signaling is implicated in many disease states including cardiomyopathies, neuropathies, and 
cancer. Multiple factors complicate dissection of GPCR-G protein signaling in live cells. First, 
there is an imbalance between the number of distinct GPCRs and G proteins. For example, in the 
human genome, there are over 700 GPCRs but only 16 G proteins. Next, GPCRs are known to 
adopt multiple structural conformations and differentially activate functionally distinct G 
proteins through mechanisms that are poorly understood. Additional complexity arises from 
differences in cellular GPCR and G protein concentrations, localization of GPCR and G protein 
to micro-domains, and regulation by regulatory elements (RGS’s, GRKs, and arrestins). How the 
cell prevents misfiring and interprets cross talk between different GPCR-G protein interactions 
remains an ongoing area of research. Studies presented herein aim to understand the mechanisms 
of specificity and multiplicity of GPCR signaling in live cells.  
The first set of studies explores the mechanisms by which GPCRs selectively activate one 
or more G proteins. Sensors were designed based on the well-established interaction between 
GPCRs and peptides derived from the Gα C-terminal α5 helix, a known determinant of the 
specificity of GPCR-G protein interaction. Proof-of-concept studies demonstrate that the Gα C-
terminus probes for a G protein-selective conformation of GPCRs in live cells. Following ligand 
stimulation, G protein-activating GPCR conformations interact specifically with the 
corresponding Gα C-terminus. Additional collaborative efforts using molecular dynamic 
simulation (MD), revealed hot spot residues on the Gαs and Gαq C-termini that confer 
specificity of GPCR-G protein interactions. A second set of MD and functional studies identified 




A parallel set of studies examines the influence of GPCR and G protein concentration and 
interaction strengths on downstream second messenger response. Therein, the well-characterized 
ER/K linker was leveraged to tether GPCRs to G proteins. The ER/K linker sets the effective 
concentration of the tethered GPCR-G protein and thus enabled a pairwise comparison across 
fusions. Linker length systematically modulated association between cognate and non-cognate G 
proteins; however, it only tuned cognate second messenger response downstream of the Gs, Gi, 
and Gq coupled receptors. Agonist stimulation provides changes in FRET (ΔFRET) comparable 
to those previously reported using co-expressed FRET/BRET pairs. Hence, the SPASM sensors 
serve the dual purpose of probing agonist-stimulated changes in GPCR-G protein interaction 
while examining the downstream response using the same construct. 
These two parallel approaches seek to better understand the mechanism regulating 
multiplicity in the GPCR-G protein signaling pathway. Findings shed light into the structural 
basis of GPCR activation and provide a mechanism for ligand-dependent GPCR-G protein 
selection. Initial studies provide proof of concept for the use of fusions to probe the multiplicity 
of GPCR-G protein signaling in live cells, however, additional research is needed to explore the 




 A brief introduction to GPCR-G protein signaling  
 
 1.1 Overview of GPCR signaling pathway 
 G protein coupled receptors (GPCRs/receptors) transmit detection of a wide range of ligands 
including neurotransmitters, hormones, odorants, photons, chemokines, calcium ions, and drugs 
from the extracellular milieu to the inside of the cell, by interacting with heterotrimeric G 
proteins, consisting of α, β and γ subunits (1, 2). GPCR binds and activates G protein by 
inducing nucleotide exchange from GDP (guanine diphosphate) to GTP (guanine triphosphate). 
Signal amplification occurs as GTP bound G protein, functionally dissociates in to GαGTP and 
Gβγ subunits to activate their respective effectors, resulting in secondary messenger production 
(1). The G proteins are categorized based on the kind of effectors they activate (see Table 1.1). 
Family Subunit Expression Example of GPCRs Effector Second Messenger 




receptor D1 (D1R) 
Adenylyl cyclase 
(AC) cAMP ↑ 
Gi 
Gαi Mostly ubiquitous 
α2-AR, A1 adenosine 
receptor (R), 
cannabinoid receptor 
type 1 (CB1) 
Adenylyl cyclase 
(AC) cAMP ↓ 
Gαt Retina Rhodopsin cGMP- phosphodiesterase cGMP ↓ 
Gq Gαq Ubiquitous α1-AR, vasopressin 1A receptor (V1AR) 
Phospholipase C 
(PLC) IP3, DAG, Ca
2+ ↑ 








AC I    
AC II, IV, VII  
Ca2+ channels  
K+ channels 
IP3, DAG, Ca2+ ↑ 





Table 1.1: Gα subunit classification and function.  Adrenergic receptor (AR), increase ↑, decrease ↓. 
Table modified from Milligan and Kostenis BJP 2006 (2).  
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Gs and Gi proteins act on adenylyl cyclase to stimulate and inhibit cAMP production 
respectively (1). Gq activates phospholipase C (PLC) to generate inositol 1,4,5 phosphate (IP3) 
and diacyl glycerol resulting in a release of Ca2+ from the endoplasmic reticulum (1). Gβγ 
subunits can also signal through Gα’s effectors and others including potassium channels, 
calcium channels, and PI3-kinase type C (2-4) (Table 1.1). GPCR signaling is attenuated by 
receptor phosphorylation by G protein receptor kinases (GRKs) and subsequent binding of 
arrestins, resulting in clathrin dependent endocytosis and desensitization (Fig. 1.1a) (1, 3).  
 
1.2 Physiological relevance of GPCR signaling 
GPCR signaling is involved in a wide range of physiological processes, including sensory 
perception (sight, smell, and taste), behavioral and mood regulation, inflammation and immune 
response, cell growth and cell death, and regulation of cardiac, pulmonary, and digestive 








































Fig. 1.1: GPCR signaling via G proteins and β-arrestins. a. Canonical GPCR signaling pathway. In 
the canonical pathway, agonist bind to GPCRs and stimulate second messenger response via G proteins, 
whereas signaling is attenuated by phosphorylation via GRKs and subsequent binding of β-arrestin 
leading to GPCR internalization and desensitization.  b. Current model of GPCR signaling. Recent 
studies strongly suggest that agonist binding stimulates GPCR signaling via G proteins and β-arrestin, in 
addition to internalization and desensitization via β-arrestins. c. Biased agonism. In the case of biased 
agonist, (β-arrestin biased agonist is shown as an example), signaling proceeds through one pathway. 
Figure modified from Rajagopal et al., Nat Rev Drug Disc. 2010 (3). 
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processes (1, 5). As such, dysfunction in GPCR signaling machinery has been implicated in a 
wide range of disease states. Currently, over 30% of prescribed drugs directly or indirectly target 
a GPCR for treatment of diseases of every major organ system including the nervous, 
respiratory, metabolic, urogenital, and cardiovascular systems (6, 7).  
In 2013, Center for Disease Control and Prevention reported heart disease as the leading cause of 
death in the United States. β-blockers targeting β-adrenergic receptors are the most common type 
of drugs used to treat cardiovascular diseases including hypertension, angina, myocardial 
infarctions, and heart failure (7). Two β-adrenergic isoforms, β1 and β2 are expressed in the 
human heart. β-ARs regulate cardiac inotropy (contractility) and chronotropy (heart rate) (7, 8). 
In response to catecholamines (e.g. norepinephrine), which are the endogenous ligands for 
adrenergic receptors, β-ARs activate Gs to stimulate cAMP production resulting in activation of 
cAMP dependent protein kinase A (PKA) (7). PKA modulates cardiac contractility by 
phosphorylating myocyte proteins such as the L-type Ca2+ channel, resulting in increase in Ca2+ 
release and myofilament contraction (7). In contrast, Gi signaling reduces cAMP levels, slows 
down heart rate, and reduces contractility (8). During heart failure, levels of catecholamines 
increase, as the system attempts to enhance cardiac output by signaling through β-AR-Gs 
pathway (9). Interestingly, β1-AR to β2-AR ratio changes from 80:20 to 60:40 in a failing heart, 
with a correlative increase in Gi signaling (10, 11). Diminished contractile responsiveness to β-
AR stimulation and an increase in Gi signaling are together the hallmarks of heart failure (7, 8). 
Additional studies suggest that during heart failure β2-AR switches signaling from Gs to Gi (Fig. 
1.2) (9, 12-14).   
Fig. 1.2: Schematic of β2-AR-G protein signaling in the human heart. Cardiac receptor β2-AR has 
been suggested to signal through Gs and Gi. However, the molecular basis of β2-AR’s signaling via to 













1.3 Multiplicity of GPCR signaling  
This multiplicity in GPCR signaling is not unique to adrenergic receptors, and has been 
demonstrated for a wide range of GPCRs, including a cardiac, Gq coupled, Angiotensin II type 
1A receptor (AT1AR) (4, 15). Differential AT1AR phosphorylation by GRKs result in unique 
signaling output (16). The endogenous angiotensin II (AII) ligand promotes Gαq mediated 
increase in cytosolic Ca+2, transportation of PKCα to the membrane, and subsequent receptor 
phosphorylation by GRKs (17) (Fig. 1.1a). GRK2 and GRK3 mediate receptor endocytosis, 
desensitization, and internalization (16) (Fig. 1.1a). Whereas, AT1AR phosphorylation by GRK6 
results in β-arrestin2 recruitment and signaling via the Extracellular-signal regulated kinase 
(ERK) pathway (Fig. 1.1b, Fig. 1.3) (16).  
In comparison, SII peptide ‘biases’ AT1AR signaling pathway to arrestins (Fig. 1.1c) (18). SII, an 
artificial mutant peptide, has lower binding affinity and poorly activates the Gq pathway (15, 
18). Instead, SII recruits and induces a conformational change in β-arrestin to activate ERK1/2 
(Fig. 1.1c, Fig. 1.3) (19, 20). In contrast to AII, SII dependent ERK1/2 phosphorylation relies 
solely on GRK6 dependent recruitment of β-arrestin (Fig. 1.3) (20, 21). In the physiological 
context, both ligands induce positive ionotropic and lusitropic effects in adult rat cardiomyocytes  
(21). However, only SII response is dependent entirely on GRK6 whereas in the GRK6-/- KO 
mice, the positive ionotropic response is preserved following AII stimulation (21).  
Additional studies reveal that spatiotemporal localization and kinetics of ERK1/2 
phosphorylation are vastly differently as a result of G protein activation or via β-arrestin 
recruitment (22). G protein dependent activity is rapid, transient, and peaks within 2-5 minutes of 
activation (22, 23). PKC inhibitor Ro-31- 8425 blocks this activity; however, it is insensitive to 
depletion of endogenous β-arrestins (22). In contrast, β-arrestin activation is slower, less robust, 
and shows little decrement over 30 minutes (22). This response is insensitive to G protein 
inhibitors, but sensitive to levels of β-arrestin, as siRNA knockdown of β-arrestin significantly 
diminishes this activity (22). Subsequent drug screens have lead to discovery of drugs that do not 



































































Fig. 1.3: Multiplicity of AT1R signaling. Cardiac receptor AT1R has been suggested to signal  
through Gq and arrestins. Gq pathway: The endogenous ligand, AII (aquamarine circle) stimulates Gαq 
mediated increase in IPx and Ca+2 levels and subsequent receptor phosphorylation by GRK 2, 3, and 6. 
An increase in cellular Ca+2 and DAG levels stimulate PLC, resulting in downstream phosphorylation of 
ERK1/2 via the Raf/Ras pathway. Phosphorylation of ERK1/2 is robust but transient, and the 
phosphorylated ERK1/2 translocates to the nucleus. AT1R phosphorylation by GRK6 (shown in blue) 
results in arrestin mediated ERK1/2 signaling. Phosphorylated ERK1/2 is retained in the cytosol. AT1R 
phosphorylation by GRK2 (depicted in red), recruits arrestins to initiate clathirin mediated endocytosis 
resulting in either lyosomal degradation or recycling of the inactive AT1R to the plasma membrane. SII 
ligand (black circle), stimulates GRK6 response resulting in ERK1/2 signaling independent of Gq 
signaling.  
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1.4 Role of structural diversity in multiplicity of GPCR signaling  
Recent studies have emphasized the role of GPCR conformations in the multiplicity of GPCR 
signaling. An emerging view from spectroscopic, biophysical, molecular dynamics, biochemical, 
and functional studies support the idea that GPCRs are not simple on or off switches (15, 25-30). 
These studies posit that GPCRs exist in an ensemble of conformations, where ligand binding 
stabilizes a subset of these conformations that are selective for downstream effectors, and thus 
result in activation of distinct G proteins and/or arrestin (25). 
This concept slowly developed over the past few decades. Studies done on the prototypical 
receptor rhodopsin formed the basis for one of the first models of GPCR signaling (31). 
Rhodospin consists of apoprotein opsin covalently bound to inverse agonist 11-cis-retinal, and is 
required for sensation of low light levels (32). In situ conversion of the inverse agonist to a full 
agonist occurs following photon absorption as 11-cis-retinal isomerizes to 11-trans-retinal (31). 
Site-directed-spin labeling experiments with bovine rhodopsin demonstrated an outward 
movement of the transmembrane (TM) helix 6 in the active conformation (33). As such, 
rhodopsin goes from an inactive state to a fully activate conformation (33). This lead to a 
bimodal model of GPCR signaling, where receptors were thought to exist in two distinct inactive 
(‘off’) or active (‘on’) conformations with ligand binding promoting structural rearrangements of 
the 7-transmembrane bundle (34).  
Multiple active conformations were inferred from the fluorescent studies on purified β2-AR (35). 
Fluorescence Resonance Energy Transfer (FRET) sensor was generated in a minimal cysteine 
background. FRET reporters were inserted into the cytosolic end of transmembrane helices 3 and 
6 by mutating Ile135 and Ala271 to tryptophan (FRET quencher) and cysteine respectively (35). 
Cys271 was subsequently labeled with monobromobimane (35). Experiments with full agonists, 
partial agonist, antagonist, and inverse agonist produced stepwise changes in fluorescence 
suggesting that agonists stabilize different conformational states of the receptor (35). 
Comparatively, live cell GPCR FRET sensors were generated by genetically inserting YFP 
(FRET acceptor) into the third intracellular loop of the receptor, and fusing CFP (FRET donor) 
to the GPCR’s C-tail (36) (Fig. 1.4a). FRET studies using these sensors in intact cells also 
demonstrated that agonists and partial agonists induce distinct FRET signals with highly variable 
kinetics (36).  
 
 7 
1.5 Challenges in exploring mechanism of multiplicity of GPCR signaling in live cells 
 Despite these initial observations, the molecular basis of how ligands acting on the same GPCR 
induce signaling via one or more distinct G proteins and/or arrestins remains an open area of 
research (37). Dissecting this phenomenon in live cells poses a significant challenge.  In general, 
functional studies in cells, membranes, or tissue preparations have shown that ligand treatment 
results in a complex response with changes in multiple secondary messengers including cAMP, 
IPx, K+, and Ca2+ as well as signaling via ERK1/2 pathway (4). As alluded to above, G protein 
signaling pathway and arrestin converge on ERK1/2. ERK1/2 activation occurs by multiple 
mechanisms (1, 38). Gs, Gi/o and Gq/11 proteins activate ERK1/2 pathway. Gαs-dependent 
























Fig. 1.4: GPCR-G protein fluorescence or bioluminescence sensors. Schematic of the previously 
described (a,b) and proposed (c,d) GPCR conformation (a, c) and GPCR-G protein interaction sensors 
(b,d). a. Previously described GPCR conformation sensors involved labeling the third intracellular loop 
with FRET or BRET acceptor (YFP) and C-tail with FRET or BRET donor (CFP or luciferase 
respectively).  b. Previously reported GPCR-G protein interaction sensors involved co-transfecting 
individually labeled GPCR and G protein in live cells. Proposed sensors involve generating a single 
polypeptide by fusing in frame Gα α5 peptide (c) or Gα (d) to the C-terminus of the GPCR with an 
ER/K linker flanked by the FRET pair (mCitrine and mCerulean).  
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resulting in sequential phosphorylation of ERK1/2. Likewise, Gq mediated increase in cellular 
Ca+2 and DAG levels stimulate PLC, resulting in downstream phosphorylation of ERK1/2 via the 
Raf/Ras pathway (Fig. 1.3) (1). Similarly Gβγ subunits of heterotrimeric Gi protein, can activate 
the phosphoinositide 3-kinase (PI-3K) resulting in ERK1/2 phosphorylation via recruitment of 
SOS1 and Raf (2). Arrestins are thought to serve as scaffolds of the MAPK pathway, recruit c-
Src, Raf/Ras, and thus enhance phosphorylation of MEK1/2 and ERK1/2 (19). 
To compound the problem further, multiple layers of complexity contribute to the 
multiplicity of the downstream second messenger response (Fig. 1.5) (4, 37).  
Cellular/environmental factors including differential expression of GPCR and G proteins in 
different cell types, localization to different membrane compartments such as microdomains, 
posttranslational modification by kinases, and regulation by scaffolds, RGS proteins, and 
arrestins, contribute to generation of a complex signaling response (4). Multiplicity of signaling 
can also arise from activation of the same G protein (4). The Gα and Gβγ subunits may act on 
the same or two different effectors (4) (Table 1.1). Next, a GPCR can have multiple isoforms 
expressed within the same cells, each of which can have distinct pharmacological properties as 
seen by preferential activation of one G protein compared to another (4). Thus, stimulation with 
an agonist can result in activation of distinct G proteins via different GPCR isoforms (4). Finally, 























Fig. 1.5: Complexity in GPCR-G protein 
signaling. Treatment with GPCR ligand can result in 
a production of a complex second messenger 
response. Multiplicity of GPCR signaling can arise at 
three levels: (i) GPCR, (ii) G proteins or (iii) the 
cellular environment. (i) A GPCR can have multiple 
isoforms with different subtypes expressed in the 
same cell. Each subtype can have distinct 
pharmacological properties, with differences in 
agonist affinity and preferential activation of one or 
more unique G proteins. (ii). G proteins can act on 
the same effector to modulate second messenger 
response. (iii) Cellular environmental factors such as 
relative localization and concentration of GPCR and 
G protein add yet an additional layer of complexity. 
This pattern of multiplicity can pose a challenge in 
tracing the pathways that result in second messenger 
response post ligand stimulation in live cells.	
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distinct G protein (4). Together, this complexity poses a challenge in tracing the individual 
pathways that connect ligand stimulation to second messenger response. The central aim of this 
thesis is to shed insight onto the molecular mechanisms that influence multiplicity of GPCR 
signaling in live cells.  
 
1.6 Novel tools to explore the molecular basis of multiplicity of GPCR signaling 
Although, spectroscopic studies elegantly demonstrated ligand-specific conformations, prior to 
this thesis’s work, there was no direct link between GPCR conformations and downstream 
signaling in the absence of pre-documented functional response of ligand in live cells or 
membrane preparations. This limitation was partly addressed by building a complementary 
FRET sensor that reports on the relative stabilization of different G protein specific GPCR 
conformations in live cells.  
FRET sensors are based on a technique termed Systematic Protein Affinity Strength Modulation 
(SPASM) which involves the fusion of a native 
peptide from the C terminus of a G subunit to the C 
terminus of the intact GPCR via a flexible ER/K 
linker flanked by a FRET pair (mCitrine - FRET 
acceptor; mCerulean – FRET donor) (Fig. 1.4c) (39, 
40). Multiple studies have established Gα C-terminus 
as one of the key determinants of specificity of 
GPCR-G protein interaction and as an important 
component of the GPCR-G protein-binding interface 
(41-44). Crystal structures of opsin and β2-AR in 
complex with a Gαt C-terminal peptide (45) and 
nucleotide empty Gs (46) respectively demonstrate 
that the Gα C-terminus binds into the cytosolic core 
of the 7-transmebrane bundle (Figure 1.6). Following studies with amide hydrogen-deuterium 
exchange mass spectroscopy further demonstrated that the C-terminus of the Gαs α5 helix 
remains buried within the agonist-bound β2-AR (47). Hence, in Chapter 2 we propose that 
peptides derived from the Gα C terminus could be used as “bait” to detect G protein-selective 
conformations of a GPCR. 
Fig. 1.6: β2-AR-Gαs interface. Crystal 
structure of the β2-AR-Gαs complex is 
shown. Gαs C-terminal α5 helix (red) 
inserts into the cytosolic core of the 
active conformation of receptor (blue). 
(PDB: 3SN6). 
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SPASM sensors are distinct from established FRET-based GPCR sensors that rely on the 
insertion of a FRET probe in the third intracellular loop of the GPCR with its pair 
(donor/acceptor) at the GPCR C terminus (Fig. 1.4a and c). Previous BRET/FRET sensors report 
on the conformational diversity of the GPCR post ligand treatment. In comparison, The SPASM 
sensors use a peptide comprising the α5 helix of a Gα C terminus (see Table 1.2) to probe the 
stabilization of GPCR conformations that favor interactions with the corresponding G protein.  
 
An important caveat is that Gα C-terminus is one element of the GPCR-G protein interface. The 
co-crystal structure of active conformation of β2-AR in a complex with a nucleotide empty state 
of Gs protein at 3.5Å resolution revealed an extensive interface between β2-AR and Gs (Fig. 1.6) 
(46). The interface consists of β2-AR’s intracellular loop 2 (ICL2) and transmembrane 5 (TM5) 
and TM6, with Gαs elements including α5 helix, αN-β1 junction, and α4 helix. In addition, β2-
AR’s ICL2 and the E/DRY motif make long distance (9-10Å), charged interactions with Gαs N-
terminal α5 helix (46, 48). Therefore, to understand how GPCR-G protein interaction influence 
downstream second messenger response, we constructed full-length GPCR-G protein SPASM 
sensors.  
Currently, efforts to monitor and understand the link between GPCR-G protein interactions and 
downstream second messenger response are also complicated by the range of cellular factors 
listed and described above (Fig.1.4) (4). Current approaches to visualize GPCR-G protein 
Gα α5 helix Peptide name Sequence 
Gαt t-pep DTQNVKFVFDAVTDIIIKENLKDCGLF 
Gαi i-pep DTKNVQFVFDAVTDVIIKNNLKDCGLF 
Gαq q-pep DTENIRFVFAAVKDTILQLNLKEYNLV 
Gαs s-pep DTENIRRVFNDCRDIIQRMHLRQYELL 
Gαs s17 DCRDIIQRMHLRQYELL 
Gαs s11 QRMHLRQYELL 
Gαs scram CLDYNRFIHIDQRLNEMERTDQIRLRV 
Control no-pep GSGGSGGSGGSG 
Table 1.2: Sequence of Gα C termini peptides used to construct GPCR-peptide-FRET sensors. 27 
residues were derived from the α5 helix of the indicated Gα C terminus. Negative controls were made 
by creating a no-pep sensor, which contains repeating GSG sequences, or ‘scram’ peptide where s-pep 
residues were scrambled using a sequence randomizer tool. 
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interaction in cells involve probing the interaction between individually expressed fluorescent or 
luminescent protein fusions using FRET or bioluminescence resonance energy transfer (BRET) 
(49-53) (Fig.1.4b). Therefore, insights into the GPCR-G protein interaction gained from these 
studies are limited by their dependence on the relative concentration and co-localization of 
individually expressed GPCR and G protein. Alternatively, direct GPCR-G protein fusions 
generated by tethering the N-terminus of the Gα to the GPCR’s C-tail with a short or no linker in 
between have been used to study the influence of tethering different G protein subunits on G 
protein activation and second messenger signaling (54, 55). Such fusions have not been used to 
monitor the GPCR-G protein interaction using resonance energy transfer approaches (52). A 
limitation of direct fusions is that GPCRs with short C-tails do not efficiently signal to the 
tethered G protein (56-59).  
In Chapter 3, we combined the strengths of FRET and fusion proteins by leveraging SPASM, 
which involves expression of a single polypeptide encoding a GPCR tethered to a G protein via 
an ER/K α-helix/linker that is flanked by a pair of FRET probes (mCitrine (FRET acceptor) and 
mCerulean (FRET donor) (Fig.1.4d). Unstructured (Gly-Ser-Gly)4 linkers are inserted in between 
each component to provide rotational flexibility. Similar to GPCR fusions, GPCR SPASM 
sensors enable control over GPCR-G protein stoichiometry and co-localization. Increasing ER/K 
linker length from 10-30 nm has been shown to systematically modulate the effective 
concentration of the protein-protein interaction from 100nM to 10µM (39, 40, 60, 61). As part of 
a proof-of-concept study, SPASM sensors are made for four full length GPCRs with varying C-
tail lengths: β2-adrenergic receptor (β2-AR), α2-adrenergic receptor (α2-AR), α1-adrenergic 
receptor (α1-AR), and adenosine type 1 receptor (A1R). Each GPCR was tethered to functionally 
distinct Gα subunits (Gαs-XL, Gαi1, and Gαq) to bridge the gap between the GPCR-G protein 
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Chapter 2 
 Detection of G protein selective G protein-Coupled Receptor 
(GPCR) conformations in live cells* 
*Adapted from: Rabia U. Malik, Michael Ritt, Brian T. DeVree, Richard R. Neubig, Roger K. 
Sunahara, and Sivaraj Sivaramakrishnan, (2013) J. Biol. Chem 288(24) 17167-78 
 
2.1 Abstract 
While several recent studies have reported that GPCRs adopt multiple conformations, it remains 
unclear how subtle conformational changes are translated into divergent downstream responses. 
In this study, we report on a novel class of FRET-based sensors that can detect the 
ligand/mutagenic stabilization of GPCR conformations that promote interactions with G proteins 
in live cells. These sensors rely on the well-characterized interaction between a GPCR and the c-
terminus of a Gα subunit. We use these sensors to elucidate the influence of the highly 
conserved E/DRY motif on GPCR conformation. Specifically, E/D but not R mutants of the 
E/DRY motif are known to enhance basal GPCR signaling. Hence, it is unclear whether ionic 
interactions formed by the E/DRY motif (ionic-lock) are necessary to stabilize basal GPCR 
states. We find that mutagenesis of the β2-AR E/DRY ionic-lock enhances interaction with Gs. 
However, only E/D but not R mutants increase G protein activation. In contrast, mutagenesis of 
the opsin E/DRY ionic-lock does not alter its interaction with transducin. Instead, opsin-specific 
ionic interactions centered on residue K296 are both necessary and sufficient to promote 
interactions with transducin. Effective suppression of β2-AR basal activity by inverse agonist 
ICI 118,551 requires ionic interactions formed by the E/DRY motif. In contrast, the inverse 
agonist metoprolol suppresses interactions with Gs and promotes Gi binding, with concomitant 
pertussis-toxin sensitive inhibition of adenylyl cyclase activity. Taken together, these studies 
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validate the use of the new FRET sensors while revealing distinct structural mechanisms for 
ligand-dependent GPCR function.  
 
2.2 Introduction 
A fundamental unanswered question in GPCR signaling is the role of GPCR structural 
conformations in G protein selection. An emerging view from several studies is that GPCRs are 
not simple ‘on-off’ switches, but adopt a continuum of conformations (1). Structural studies 
show that ligands stabilize different subsets of structural conformations (2-5). In turn, these 
ligands are observed to elicit diverse functional responses through the activation of specific G 
protein heterotrimers or G protein independent effectors such as arrestins (6). This model would 
explain the phenomenon of functional selectivity, wherein the same GPCR can elicit diverse 
ligand-dependent responses (7,8). However, currently there is no method to directly link ligand-
specific changes in GPCR conformations to differential downstream responses (9). This 
limitation arises in part due to the wide range of factors that influence GPCR signaling, including 
differential expression of the GPCR and components of the G protein heterotrimer in different 
cell types, localization to different membrane surfaces or micro-domains, and the influence of 
regulatory proteins such as scaffolds, RGS proteins, kinases, arrestins, and the cellular endocytic 
apparatus. In this study, this limitation is addressed in part with a novel FRET-based sensor that 
is designed to detect the relative stabilization of G protein specific conformations of the same 
GPCR.  
The FRET sensors used in this study are based on a recently developed technique termed 
Systematic Protein Affinity Strength Modulation (SPASM) and involve the fusion of a native 
peptide from the c-terminus of a Gα subunit to the c-terminus of the intact GPCR (10). The Gα 
c-terminus has been extensively characterized as an important component of the GPCR-G 
protein binding interface (11-13). Recent structures reveal that the Gα c-terminus inserts itself 
into a cytosolic groove formed in the active GPCR (14-16). Peptides derived from the Gα c-
terminus bind specifically to the activated GPCR (11,17) and can competitively inhibit GPCR-G 
protein interactions (13). The Gα c-terminus is also a key determinant of G protein selection by a 
GPCR (18,19). The SPASM sensors use a peptide comprising the α5-helix of a Gα c-terminus to 
probe the stabilization of GPCR conformations that favor interactions with the corresponding G 
protein. In this regard, the SPASM sensors are distinct from established FRET-based GPCR 
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sensors that rely on the insertion of a FRET probe in the third intracellular loop of the GPCR 
with its pair (donor/acceptor) at the GPCR c-terminus (4). 
In this study, SPASM sensors were used to examine the conformational changes 
accompanying ligand-stimulation or mutagenesis of opsin and β2-AR. Specifically, we address a 
long-standing paradox in the function of the highly conserved E/DRY motif located at the 
cytosolic face of the GPCR (20,21). High-resolution structures of GPCRs bound to canonical 
inverse agonists display electrostatic interactions (termed the ionic-lock) between the positively 
charged arginine (R) in the E/DRY motif and two negatively charged residues (glutamic acid (E) 
or aspartic acid (D)) (21,22). In contrast, in high-resolution structures of GPCRs bound to 
canonical agonists these residues move apart such that the ionic-lock appears to be disrupted 
(15,21). Therefore, the E/DRY ionic-lock has been proposed to stabilize conformations that 
suppresses basal signaling (20). Consistent with this model, mutagenesis of the E/D residues that 
form the ionic-lock typically result in constitutive (ligand-free) signaling from the GPCR 
(20,23). However, mutagenesis of R (E/DRY) does not result in constitutive signaling from the 
GPCR (20). The paradoxical effect of R mutants has muddled the simple model of the E/DRY 
motif as an ionic-lock. In this study, we use the SPASM sensors to show that mutagenesis of 
either R or E/D residues in the E/DRY motif of the β2-adrenergic receptor (β2-AR), enhances 
β2-AR interactions with Gs. However, only E/D but not R mutants increase constitutive GPCR 
signaling, consistent with our finding that the R mutant does not enhance G protein activation. 
Opsin represents a notable exception to the function of the E/DRY motif, since it has a 
second ionic-lock formed by residue K296 at the ligand-binding site (24). This second ionic-lock 
is unique to opsin, which covalently binds to its ligand through the formation of a protonated 
Schiff-base at K296 (25). We find that the K296 ionic-lock dominates the effect of the E/DRY 
motif, such that E/DRY mutants do not enhance ligand-free interactions with the G protein. In 
contrast, the intact E/DRY ionic-lock in β2-AR is only observed in high-resolution structures 
obtained in the presence of inverse agonists that suppress its ligand-free activity (22). Here, we 
demonstrate that an intact E/DRY ionic-lock is necessary for effective suppression of β2-AR 
basal signaling by the potent inverse agonist ICI118,551.  
Inverse agonist suppression of basal β2-AR signaling can be achieved either by reducing Gs 
or enhancing Gi activity. Hence, SPASM sensors were used to probe ligand-biased 
conformations of two beta-adrenergic inverse agonists, ICI118,551 (ICI) and metoprolol (6,26). 
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We find that metoprolol but not ICI stabilizes conformations that enhance interaction with Gi (Gi 
conformations). Distinction between Gs suppression and Gi activation is routinely achieved by 
treatment of cells with pertussis toxin (PTX), which covalently modifies Gi and prevents its 
coupling to the GPCR (27). PTX treatment has been previously used to uncover a Gi mediated 
ERK signaling pathway initiated by β2-AR (6). However, PTX has not been used to examine G 
protein selection by ICI and metoprolol. We find that stabilization of Gi conformations by 
metoprolol correlates with a PTX-sensitive suppression of cAMP accumulation for this 
compound. In contrast, cAMP suppression by ICI118,551 is not PTX-sensitive. Taken together, 
this study validates a new technology to examine G protein-specific GPCR conformations in live 
cells, while providing new insights into the structure-to-function link for opsin and β2-AR. 
 
2.3. Results 
2.3.1. SPASM sensor expression and receptor function - SPASM sensors were developed for two 
prototypical GPCRs: β2-AR and opsin (Fig. 2.1a). Each SPASM sensor contains - from N-to-C 
terminus - a GPCR, mCitrine (FRET acceptor), ER/K linker, mCerulean (FRET donor) and a 27 
amino acid peptide (x-pep; x denotes the type of Gα subunit – t, s, i, q; t-mod is a modified 
peptide that interacts with high affinity to activated rhodopsin (17)) derived from the α5 helix of 
the Gα c-terminus (see Methods). In addition, we developed sensors containing only the receptor 
(no-pep), which were used to measure background FRET, cyclic AMP (cAMP) levels, ligand-
binding affinities and G protein activation. Intact sensor protein localized primarily at the plasma 
membrane (Fig. 2.1b,c). β2-AR sensors display a functional response (cAMP) to agonist 
treatment (isoproterenol - ISO), which can be suppressed by the potent inverse agonist 
ICI118,551 (ICI) (Fig. 2.1d). Over-expression of β2-AR-no-pep sensors (500±100 fmol/mg) 
resulted in a substantial increase in basal cAMP relative to untransfected control (Fig. 2.1d). The 
elevated basal cAMP levels for β2-AR are consistent with previously reported basal activity for 
this GPCR (31). The specificity of this basal signaling was evident in the reduction in basal 
cAMP levels following inverse agonist (metoprolol or ICI) treatment (Fig. 2.1d). For the 
consistent level of sensor expression (see Methods) used throughout the study, sensors are 
expressed at least 5-fold in excess of endogenous Gαs, Gαi2 and Gαq (Fig 2.2a,b). Over-
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expression of Gα subunits (> 5-fold) relative to untransfected levels does reduce the basal FRET 
in a Gα subtype specific-manner (Fig. 2.2c,d). 
 
2.3.2. Validation of SPASM sensor response – The SPASM sensors are designed for FRET-
based detection of ligand/mutagenesis-induced stabilization of GPCR conformations that favor 
interactions with different G proteins (Fig. 2.3a) (10). Several studies have shown that peptides 
derived from the Gα c-terminus interact with the GPCR following stimulation with canonical 
agonists (11-13). Further, the ligand-stimulated GPCR preferentially interacts with the Gα c-
terminus that it signals through (18,19). Accordingly, activation of opsin (9-cis-retinal + light) 
results in a greater FRET gain (ΔFRET ratio) for the opsin-t-pep compared to the opsin-s-pep 
sensor (Fig. 2.3b). The opsin-t-mod sensor uses the previously identified modified t-peptide that 
binds with a higher affinity than native t-pep, and correspondingly shows a larger ΔFRET ratio 
compared to the other sensors (Fig. 2.3b). Given that FRET-based detection involves excitation 
of the sample with light (430 nm) that photoisomerizes 9-cis retinal (< 600 nm), resulting in the 
activation of dark rhodopsin, the ΔFRET ratios presented here compare ligand-free opsin with 
light-activated rhodopsin (metarhodopsin (14)). In contrast, agonist (ISO) stimulation results in 
enhanced FRET for β2-AR-s-pep but not for the t-pep, i-pep or q-pep sensors (sample spectra 
Fig. 2.3c,d; compiled data Fig 3e). This is in accordance with the canonical coupling of β2-AR to 
Gs following activation (Fig. 2.1d). We note that the Gα c-terminus peptides used in this study 
are 27 amino acids long, essentially encompassing the entire α5 helix of the Gα subunit (12). 
This length of peptide was selected to potentially preserve their helical structure. Regardless of 
peptide length, the FRET gain for the β2-AR-s-pep sensor is preserved for three different length 
native peptides (Fig. 2.3e (inset); s11, s17 and s-pep contain respectively the last 11, 17 and 27 
amino acids of the Gα c-terminus; x-pep (Fig. 2.3a) contains the last 27 amino acids of the Gαx 
c-terminus). This result is consistent with the involvement of only the last 11 amino acids in the 
GPCR-G-protein binding interface (11). Specificity in the FRET gain is further evident in the 
concentration dependence of the ISO response (Fig. 2.3f). The FRET gain at saturating ISO 
concentrations (100 µM) can be competitively suppressed by the potent inverse agonist ICI (Fig. 
2.3f). As an alternative to agonist activation, the FRET levels in sensors expressing constitutively 
activating mutations, CAM and L272A (see Methods), were also examined (32,33). Introducing 
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either set of mutations in β2-AR-no-pep resulted in over a 2-fold increase in basal (ligand-free) 
cAMP accumulation, attesting to the stabilization of Gs conformations of this GPCR (Fig. 2.3g). 
Correspondingly, mutant versions of the β2-AR-s-pep sensors showed significantly elevated 
FRET levels compared to their wild-type counterparts (sample spectra Fig. 2.3h; compiled data 
Fig. 2.3i). None of the β2-AR mutants in this study alter background (β2-AR-no-pep) FRET 
levels (data not shown). The FRET ratio is an ensemble measurement of ~ 5000 cells in the 
excitation volume of the fluorometer cuvette (based on measured Optical Density (600 nm) of 
cell suspension of 0.3 for 3 mm path-length). Hence, unlike fluorescence microscopy based 
FRET evaluation in individual cells, the FRET ratio represents a bulk measurement that averages 
over potential heterogeneity across the population of cultured cells. Hence, despite the small 
changes in FRET, the differences in the measured FRET response are reproducible (Fig. 
2.3c,d,h) and statistically significant (Fig. 2.3b,e,i), with a finite spread in the distribution of 
measurements both within and across experiments (Fig. 2.3j). 
 
2.3.3. Linking E/DRY motif to receptor conformation (β2-AR versus opsin) – High-resolution 
structures of β2-AR bound to inverse agonist (Fig. 2.4a; top panel) display electrostatic 
interactions between R131 (E/DRY) and both D130 (E/DRY) and E268 (22). In contrast, these 
interactions appear significantly weaker following agonist stimulation (Fig. 2.4a; bottom panel) 
(15). While there is a correlation between the E/DRY ionic interactions and GPCR conformation, 
a causative connection between them has not been established. The D130N mutant does show 
enhanced basal signaling, suggesting the need for these interactions to suppress basal activity 
(Fig. 2.4b). However, the controversy is evidenced by the absence of enhanced downstream 
signaling upon mutagenesis of the R131 (R131A; Fig. 2.4b), despite it being essential to form the 
ionic interactions. The R131A mutant is also deficient in providing an agonist-stimulated 
functional response (Fig. 2.4c). β2-AR-s-pep sensors provide evidence for stabilization of Gs 
conformations following mutagenesis of any of the residues (D130N, R131A, E268N) that form 
the ionic interactions, and the phenotype is compounded by a double-mutant (D130N+E268N – 
D/E; Fig. 2.4d). The basal stabilization of Gs conformations is also evident in the absence of 
further FRET gain following stimulation with ISO (Fig. 2.4e). Both D130N and R131A mutants 
are capable of binding ISO as witnessed by competitive inhibition of [3H]-DHA binding to the 
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receptor in the β2-AR-no-pep sensor (Fig. 2.4f). In fact affinity of ISO binding is substantially 
enhanced for both D130N and R131A mutants compared to wild-type (Ki = 335 nM for wild-
type; Ki = 8 nM for D130N; Ki = 20 nM for R131A). These results are consistent with a 
conformational change in β2-AR, upon mutagenesis of either D130 or R131, that mimics the 
effect of G protein binding, leading to ternary complex formation (34). However, only the 
D130N but not the R131A mutant enhances G protein activation as witnessed by enhanced basal 
35S-GTPγS uptake (Fig. 2.4g). Basal 35S-GTPγS uptake is measured as the difference in 
scintillation counts (counts-per-minute - cpm) between basal and ICI118,551 (10 µM) inhibited 
conditions for 62 fmol of receptor per condition (wild-type/mutant; see Methods). This 
measurement facilitates comparison of specific 35S-GTPγS uptake resulting from equal amounts 
of the wild-type receptor, without the complication of varying levels of non-specific 35S-GTPγS 
binding caused by differential expression of wild-type and mutant sensors. Importantly, the 
affinity of ICI118,551 binding is similar between wild-type, D130N, and R131A mutant 
receptors (Ki ~ 0.1 nM; Fig. 2.4h). Taken together, these complementary approaches dissect the 
molecular basis for differential signaling from E/D and R mutants. While both E/D and R 
mutants cause conformational changes in β2-AR that enhances G protein interactions, only E/D 
but not R mutants increase G protein activation. 
In contrast, mutagenesis of either of the residues (E134N (ED/RY), R135A (E/DRY) or 
E247N; Fig. 2.5a) implicated in similar ionic interactions for opsin (35) does not alter basal 
(ligand-free) FRET levels (Fig. 2.5b). Activation of opsin (9-cis-retinal + light) provides a 
substantial FRET gain for E247N and E134N but not R135A (Fig. 2.5c). Thus, the E/DRY motif 
interactions do not appear to be necessary for stabilization of the basal state in opsin. These 
results are not surprising, given a second prominent set of opsin-specific ionic interactions that 
are also important for ligand (retinal) binding (K296, E113; Fig. 2.5d) (24). Mutagenesis of 
either of these residues (K296A/G/E, E113Q) substantially elevates basal FRET levels (Fig. 
2.5e). Presentation of counter-ions to K296 by mutagenesis of G90 (G90D) or A292 (A292E) 
also enhance basal FRET (24). Thus, the ionic interactions centered on K296 are necessary and 
sufficient to stabilize opsin in its basal state. Opsin stimulation (9-cis-retinal + light) results in a 
substantial FRET gain for wild-type, G90D, A292E and E113Q, but not K296A/E/G (Fig. 2.5f). 
The latter result is consistent with the need for the K296 residue for binding retinal (25). 
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2.3.4. Inverse agonism of β2-AR requires a functional E/DRY motif - High-resolution structures 
of the receptor bound to inverse agonists display an intact ionic-lock (Fig. 2.6a) (21,22). This 
suggests that the inverse agonist stabilizes the ionic-lock, however a causative mechanism 
remains to be established. To test this connection, the effects of the inverse agonist ICI on β2-
AR-s-pep sensors were examined in the context of WT and E/DRY motif mutants. Sensors with 
a single counter-ion (E268N or D130N) mutation showed sensitivity to ICI (suppression of 
cAMP and decreased FRET; Fig. 2.6b,c) whereas a double mutant that abolishes the ionic-lock 
(D130N+E268N) showed a reversal of FRET response with minimal suppression of constitutive 
activity (Fig. 2.6b,c). Together, these results suggest that the function of inverse agonist ICI 
requires an intact E/DRY motif. In contrast, the inverse agonist metoprolol does not affect the 
FRET levels for the D130N mutant (Fig. 2.6b). This suggests that inverse agonism of metoprolol 
is distinct from that of ICI. 
 
2.3.5. Metoprolol stabilizes Gi conformations – Inverse agonist suppression of basal cAMP 
signaling can be achieved by reducing Gs activity or enhancing Gi. While a previous study has 
demonstrated that metoprolol suppresses cAMP accumulation, it did not distinguish between 
effects on Gs and Gi (26). Metoprolol (150 µM) decreases FRET levels for the β2-AR-s-pep 
sensor, while elevating FRET levels for the β2-AR-i-pep sensor in a dose-dependent manner 
(Fig. 2.7a,b). Thus metoprolol appears to stabilize Gi conformations at the expense of those that 
promote interactions with Gs. To test whether the Gi conformations precipitates a Gi-dependent 
response, we examined the pertussis-toxin (PTX) sensitivity of the forskolin response (10 µM). 
Metoprolol inhibition of cAMP accumulation was sensitive to PTX treatment, a characteristic of 
Gi stimulation induced by a receptor-ligand combination (Fig. 2.7c) (36). In contrast, saturating 
concentrations of ICI (10 µM) did not alter basal FRET levels for either the β2-AR-s-pep or β2-
AR-i-pep sensors, nor is its inhibition of cAMP accumulation PTX sensitive (Fig. 2.7a,c). 
Together, these results suggest that metoprolol stabilizes Gi conformations in β2-AR, which in 
turn enhance coupling to Gi. 
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2.4. Discussion 
2.4.1. Detecting the stabilization of G protein specific conformations of a GPCR – The 
phenomenon of functional selectivity, wherein the same GPCR can signal through multiple 
effectors (G proteins/arrestin) is well established (8). The emerging view in the field suggests 
that GPCRs exist in a continuum of conformations with certain subsets more or less favorable for 
interactions with one or more effectors (1). Ligands stabilize non-identical subsets of GPCR 
conformations leading to their traditional classification as agonists, partial agonists, antagonists, 
inverse agonists and biased agonists (7). Recent structural studies have detected ligand-specific 
stabilization of β2-AR conformations (2-5), but do not directly link them to function in the 
absence of documented functional responses in cell or membrane preparations (6,26,37). Given 
the wide range of factors that influence the functional response, there is a need for 
complementary tools that can detect the stabilization of G protein selective conformations (9).  
A well-characterized determinant of G protein selection is the c-terminus of the Gα subunit 
(18,19). The Gα subunit inserts itself into a cytosolic groove formed in the activated GPCR 
(14,15). Hence, we hypothesized that peptides derived from the Gα c-terminus could be used as 
‘bait’ to detect G protein selective conformations of a GPCR. Sensors developed using the 
SPASM technique (10) detect ligand/mutagenic stabilization of GPCR conformations that result 
in changes in interaction with one or more G protein peptides. The enhanced G protein 
interactions can result in enhanced downstream signaling. However, the conformational states 
detected by the sensor are not necessarily identical to those that trigger G protein activation. 
Hence, sensor readout needs to be verified using complementary approaches such as examination 
of second messenger levels, ligand-binding affinities (evaluates ternary complex formation) and 
G protein activation.  
In this study we show that β2-AR, a GPCR that has been proposed to signal through both Gs 
(canonical) and Gi (37,38), displays ligand-dependent conformations that promote interactions 
with Gs and/or Gi (Gs and Gi conformations). While the classic agonist isoproterenol stabilizes 
Gs conformations, the inverse agonist metoprolol stabilizes Gi conformations (Fig. 2.7). Ligand-
free β2-AR is known to stimulate cAMP accumulation and several inverse agonists reduce this 
basal activity (26,31). Given that cAMP accumulation is regulated by both Gs and Gi, it remains 
to be established whether inverse agonists suppress Gs and/or activate Gi. Hence, pertussis-toxin 
(PTX) treatment was used to uncover a new Gi-dependent activity for metoprolol but not ICI. 
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Accordingly, only metoprolol but not ICI stabilizes Gi conformations. Together, these studies 
support the presence of Gs and Gi conformations of β2-AR that can be stabilized in a ligand-
dependent manner.  
 
2.4.2. What is the role of the E/DRY motif in GPCR conformation? – High-resolution structures 
of GPCRs stabilized bound to inverse agonists show strong electrostatic interactions centered on 
residues in the conserved E/DRY motif (22,39). In contrast, these residues move apart in 
structures of GPCRs activated with agonist (14,15). This has led to the model that the E/DRY 
ionic interactions (ionic-lock) are required to stabilize GPCRs in an inactive state (20,21). While 
structural studies support this model, they have not established cause-and-effect between ionic-
lock stabilization and GPCR inactivation. This model posits that disrupting the ionic-lock would 
be sufficient to transition the GPCR to an active conformation, resulting in constitutive (ligand-
free) activity (20). However, mutation of the acidic (E/D) but not basic (R) residues enhances 
basal activity of the GPCR as measured from the downstream functional response (cAMP) 
(20,40). Therefore, functional studies have not resolved the role of the E/DRY ionic-lock in 
GPCR conformation. In this study, the SPASM sensors were used to de-couple conformational 
changes in the GPCR (as detected by Gα c-terminus peptide binding) from the downstream 
response (cAMP) to show that for β2-AR, mutagenesis of either of the residues that form the 
ionic-lock is sufficient to enhance interactions with Gs. However, R mutants do not show 
enhanced cAMP accumulation, in line with our finding that they do not enhance G protein 
activation. Opsin is a notable exception to the role of the E/DRY motif, in that it has a second, 
unique, ionic-lock centered residue K296 at the ligand-binding interface (24). We find that 
mutagenesis of the K296 ionic-lock, but not the one formed by the E/DRY motif is sufficient to 
transition this GPCR to an active conformation. Thus, while the role of the E/DRY motif 
continues to be receptor-specific, the use of the SPASM sensors complemented with traditional 
approaches allows us to directly examine the role of intramolecular interactions on GPCR 
conformation. 
 
2.4.3. Severity of disease phenotype correlates with stabilization of a GPCR active conformation 
- Retinitis pigmentosa (RP) affects 1 in 4000 of the general population with symptoms ranging 
from night blindness to complete loss of eyesight (41). Over 25% of autosomal dominant RP 
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patients have a single point mutation in opsin, with over 120 mutations documented to date (42). 
A subset of RP mutations constitutively activates opsin by perturbing the K296-E113 ionic 
interaction within this receptor (24,43). The effects of these mutations on opsin function have 
been inferred primarily by examining signaling downstream of transducin (Gαt), such that the 
molecular mechanisms translating these mutations to differential disease phenotype remain 
poorly understood (43). Mutation of residue K296 (A/E/G) leads to severe RP, causing blindness 
(24). Mutations that introduce a destabilizing counter-ion to K296 (G90D or A292E) instead lead 
to mild RP, resulting in night-blindness (24). We report that most of these mutations (with the 
exception of G90D) increase the strength of interaction of opsin for a peptide derived from the 
transducin c-terminus. Our finding is in line with the current model of constitutive activation of 
opsin in RP (24,43). Importantly, the gain in basal affinity directly correlates with the reported 
severity of RP phenotype (K296G/A > K296E > A292E > G90D). Hence, our results support a 
model wherein the K296 mutant enhances its interaction with transducin in a retinal-independent 
manner (24,44). In contrast, the counter-ion mutants only partially populate an active 
conformation in the basal state and need a combination of retinal and light for full activity. 
 
2.4.4. Distinct mechanisms for different inverse agonists - The basal activity of β2-AR suggests 
that it samples both active and inactive states in the absence of ligand (31). Therefore, it is not 
surprising that high-resolution structures of β2-AR with an intact E/DRY ionic-lock have all 
been obtained in the presence of ligands that suppress basal signaling (inverse agonists) (22). 
While these structures suggest a connection between inverse agonists and the E/DRY motif, it 
remains to be established whether the ionic-lock is necessary for inverse agonist function. Here, 
we find that efficient suppression of β2-AR basal activity by the potent inverse agonist, 
ICI118,551, is dependent on the integrity of the E/DRY ionic-lock. Disruption of the ionic 
interactions formed by the E/DRY motif reduces ICI’s ability to suppress β2-AR basal signaling. 
In contrast, metoprolol suppresses basal activity by enhancing β2-AR interactions with Gi, rather 
than stabilizing the E/DRY ionic-lock. The distinct mechanisms of inverse agonism for 
metoprolol and ICI, along with the tools developed here to detect the relative stabilization of G 
protein selective receptor conformations need to be factored into the identification and selection 
of inhibitors that target GPCR function. 
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2.4.5. SPASM sensor toolbox - This study uses the recently developed technique termed 
Systematic Protein Affinity Strength Modulation (SPASM) to directly detect the interaction 
between a GPCR and native peptides derived from the c-terminus of the Gα subunit. The 
specificity of the FRET response is validated with two prototypical GPCRs, β2-AR and opsin 
that show selectively enhanced interaction for the c-terminus of Gαs and Gαt (transducin) 
respectively, following GPCR activation (opsin – 9-cis-retinal+light; β2-AR – ISO). Further, as 
expected, constitutively active mutants of both GPCRs display enhanced interactions relative to 
their wild-type counterparts. The enhanced FRET with agonist is dose-dependent and can be 
competitively inhibited with an inverse agonist. The FRET measurements of the sensor can be 
influenced by competition with endogenous G proteins. However, the consistent levels of sensor 
expression (± 20%) used throughout the study, along with the tools to measure expression 
relative to endogenous Gα subtypes factors in the effects of endogenous G proteins.  
The functional significance of Gi conformations mediated by metoprolol is verified by a 
standard pertussis-toxin (PTX) sensitivity assay. The studies with the E/DRY motif and the opsin 
K296 ionic-lock support existing models for their function, while providing much needed clarity 
on their influence in stabilizing GPCR conformations. Therefore, taken together, this study is a 




2.5. Experimental Procedures 
2.5.1. Buffer and Reagents - 9-cis-retinal, (-)-isoproterenol (+)-bitartrate salt, fenoterol 
hydrobromide, ICI118,551 hydrochloride, (±)-propranolol hydrochloride, (±)-metoprolol (+)-
tartrate salt, forskolin, pertussis toxin (PTX), 3-isobutyl-1-methylxanthine (IBMX), and poly-L-
lysine were purchased from Sigma-Aldrich. Bovine retinal cDNA was acquired from Zyagen. 
Human β2-adrenergic receptor (β2-AR), Gαq, Gαi2, and long splice variant of human Gαs 
cDNA clones were obtained from Open Biosystems. Gαs (sc-823), Gαq (sc-393), and Gαi2 (sc-
13534) antibodies were acquired from Santa Cruz Biotechnology Inc. Buffer A is HEPES 
buffered saline supplemented with 0.2% dextrose (w/v), 500 μM ascorbic acid and 1.5 μg mL-1 
aprotinin and 1.5 μg mL-1 leupeptin at pH 7.45.  
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2.5.2. Molecular Cloning - A modular cloning scheme was used to construct the different GPCR 
sensors. All GPCRs sensors were expressed as single polypeptides. Opsin and β2-AR were 
derived from PCR of bovine retinal cDNA and human cDNA respectively. Briefly, GPCR (β2-
AR or Opsin), mCitrine, 10 nm ER/K α-helix, mCerulean and Gα c-terminus peptide/Gα were 
sequentially cloned between HindIII, XbaI, EcoRI, AscI, PacI, NotI restriction sites in the PCS2 
vector. No-pep sensors did not contain peptide after mCerulean, and instead had a repeating 
(Gly-Ser-Gly)4 residues. Constructs were then subcloned into the PCDNA5/FRT vector between 
HindIII and NotI. A (Gly-Ser-Gly)4 linker was inserted between all protein domains as part of the 
primer sequence to allow for free rotation between domains. An N-terminal HA-tag was inserted 
in frame to all β2-AR-sensors. All mutant constructs were generated via PCR using 
oligonucleotide-directed mutagenesis (QuikChange Site-directed Mutagenesis Kit, Stratagene). 
Peptides encoded the last 27 C-terminal residues of the corresponding Gα. The following amino 
acid sequences were used: 
(1) t-mod: KQRNMLENLKDCGLF 
(2) t-pep: DTQNVKFVFDAVTDIIIKENLKDCGLF 
(3) s-pep: DTENIRRVFNDCRDIIQRMHLRQYELL 
(4) i-pep: DTKNVQFVFDAVTDVIIKNNLKDCGLF 
(5) q-pep: DTENIRFVFAAVKDTILQLNLKEYNLV.  
All constructs were confirmed by sequencing. The wild-type sensors developed for this study, 
along with detailed plasmid maps to subclone other GPCRs, are available through the AddGene 
plasmid depository (http://www.addgene.org/Sivaraj_Sivaramakrishnan). 
 
2.5.3. Sensor Protein Expression and Cell Preparation: HEK293T-Flp-in (Invitrogen) cells were 
cultured in DMEM supplemented with 10% FBS (v/v), 4.5 g/L D-glucose, 1% Glutamax, 20 mM 
HEPES, pH 7.5 at 37oC in humidified atmosphere at 5% CO2. HEK293T-Flp-in cells (Passages 
10-30) were plated into tissue-culture treated dishes at ~ 30% confluence. Cells were allowed to 
adhere for 16-18 hr followed by transient transfection of sensor plasmid DNA (pCDNA/FRT; 
Invitrogen) with Fugene HD (Promega). Transfection conditions were optimized (2.5 µg DNA + 
8 µl reagent) to reproducibly obtain primarily membrane expression of sensors 22-32 h post 
transfection (evaluated at 40x magnification on a Nikon tissue-culture microscope enabled with 
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fluorescence detection). For each experiment, expression was quantified to ensure that at least 
80% of cells expressed primarily plasma membrane-bound protein, without detectable 
localization of protein to intracellular compartments. At least 75% transfection efficiency 
(percentage of visibly fluorescent cells) was consistently achieved using this protocol. The length 
of transfection (22-32 h) was optimized for each sensor to maintain consistent expression levels 
(± 20% across experiments and sensors). Sensor expression was evaluated by fluorescence 
measurement at matched optical density of cell suspension. Cells were re-supsended by gentle 
pipetting (no trypsin/EDTA treatment) and washed once with Buffer A. Cells were re-suspended 
at fixed density for all measurements (O.D. of 0.3 (600 nm; 3 mm pathlength)). Sensor 
expression was evaluated by mCitrine fluorescence (FRET acceptor; Fluoromax-4 – Excitation 
(Ex) 490 bandpass 8 nm; Emission (Em) 500-600 bandpass 4 nm) and was held within 2.6-
3.8x106 counts-per-second. For each sensor, both mCitrine fluorescence and percentage of 
membrane expression were recorded for each experiment to ensure consistency. Cells were 
maintained at 37 oC throughout the experiment (all buffers were pre-warmed to 37o C; 
fluorometer cuvette-holder was maintained at 37 oC) and the experiment was completed within 
30 min of cell re-suspension in Buffer A (each FRET spectrum required ~ 1 min of acquisition 
time). For opsin, cells were incubated in the presence or absence of 9-cis-retinal for 1 h at 37oC 
in the dark in Buffer A. Cells were exposed to ambient light for 1 min before recording FRET 
spectra. For β2-AR experiments involving ligands, cells were aliquoted (90 µl) and ligand 
diluted in HBS buffer was added (10 µl). A matched aliquot with Buffer A (10 µl) was used as a 
control to avoid repeated measurements of the same sample. Measurements of control and 
ligand-treated conditions were performed either alternately or within 5 min of each other (no 
measurable difference between procedures). Each agonist (ISO) treated aliquot was incubated for 
3-5 min, whereas those treated with inverse agonists were incubated for 5-10 min before 
acquisition of spectra. Separate micro-cuvettes were used for control and treated samples to 
avoid cross-contamination. 
 
2.5.4. Fluorescence Resonance Energy Transfer (FRET) Measurements - FRET spectra were 
generated by exciting cells at 430 nm (spectral bandpass 8 nm), and scanning emission from 450-
600 nm (bandpass 4 nm) on a FluoroMax-4 fluorometer (Horiba Scientific). For mCitrine-only 
measurements, cells were excited at 490 nm (bandpass 8 nm) and emission was recorded from 
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500-600 nm (bandpass 4 nm). Each experimental condition for β2-AR constructs was collected 
within 30 min of re-suspension in Buffer A at 37 oC. 
  
2.5.5. Live Cell FRET Ratio Calculations - OD measurements were taken for untransfected and 
transfected cells in Buffer A; appropriate volumes of media were added to achieve an OD-600nm 
reading of 0.3 (BioRad SmartSpec Plus Spectophotometer, 3 mm path-length, quartz cuvette). 
FRET (mCerulean Ex: 430 nm, Em: 450-600 nm) emission spectra were corrected for cell-
scattering noise by subtracting spectra for untransfected HEK293 cell suspensions. FRET 
emission spectra from the FRET emission spectra of transfected cells of matched cell density 
(OD). The corrected fluorescence emission spectra were then normalized to mCerulean emission 
(475 nm). FRET ratio was measured by calculating ratio of normalized emission of mCitrine 
(525 nm) to mCerulean (475 nm). 
 
2.5.6. Quantification of cAMP Production - HEK293T-Flp-in cells were transiently transfected 
with HD-Fugene (Promega) according to the vendor’s instructions and cAMP levels were 
assessed using the cAMP Glo luminescence based assay (Promega). Where indicated, 12 h after 
transfection, cells were incubated with 100 ng mL-1 PTX for 16 h. Briefly, 24-27 h post 
transfection, cells were gently resuspended in DMEM containing 10% FBS (v/v), spun down and 
resuspended in PBS supplemented with 800 μM ascorbic acid and 0.02% glucose, and aliquoted 
into 96-well flat-bottom opaque microplates. For assessment of basal cAMP levels, cells were 
incubated with 0.5 mM IBMX/PBS for 20 min at 37oC and exposed to 150 μM metoprolol, 10 
μM ICI118,551, or buffer control for an additional 15 min at 37oC. For forskolin treatment, cells 
were incubated with 10 μM forskolin in the presence or absence of 150 μM metoprolol or 10 µM 
ICI118,551 for 15 min at 37oC.  For isoproterenol treatment, cells were pre-incubated in the 
presence of absence of 150 μM metoprolol or 10 μM ICI118,551 for 5 min and subsequently 
treated with 100 μM of isoproterenol for 3 min. After incubation with respective small 
molecules, cells were lysed and protocol was followed according to manufacturer’s 
recommendations (Promega). Luminescence was measured using a microplate luminometer 
reader (Synergy 2, BioTek). cAMP production was normalized to the total amount of  β2-AR 
sensor protein expressed as indicated by mCitrine fluorescence levels (Ex: 490 nm, Em: 525 
nm).  
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2.5.7. Live Cell Microscopy and Image Analysis - Cells were imaged at 60x magnification using 
a Nikon TiE microscope equipped with a mercury arc lamp, 63x and 100x 1.4 Numerical 
Aperture Plan-Apo oil objectives and on an Evolve 512x512 EM-Charge-Coupled-Device 
camera (Photometrics). Cells were imaged on 35 mm glass bottom dishes (MatTek Corp) coated 
with 0.001% poly-L-lysine/PBS. 16 h after plating cells on poly-L-lysine coated MatTek plates, 
cells were transfected with Mirus-LT or HD-Fugene (Promega). 18-24 h post-transfection cells 
were washed multiple times with warm Buffer A to remove excess phenol red from the media 
and were subsequently imaged in warm Buffer A. Z-stack images were taken with 1 μm steps 
and the resultant stack of images was deconvolved using AutoQuantX software.  
 
2.5.8. Membrane Preparation – Membrane preparation follows a protocol modified from Clark 
et al. (28). HEK293 cells expressing indicated sensors were washed once with ice-cold PBS 
buffer. Cells were resuspended in a ice-cold hypotonic buffer (Buffer B - 20 mM HEPES pH = 
7.4, 0.5 mM EDTA, aprotinin (1.5 μg mL-1), leupeptin (1.5 μg mL-1), 0.1 mM DTT), incubated 
for 30 min (4 oC) on a rotator, and lysed with a FisherBrand rotary pestle for 30 s. Lysated were 
cleared by centrifugation (500g, 5 min), followed by pelleting of membranes (40,000g, 20 min). 
Membranes were washed once with Buffer B + 3 µM GDP + 5 mM MgCl2 (10s resuspension 
with rotary pestle) and re-spun at 40,000g for 20 min. Pellets were resuspended in identical 
buffer to a concentration of 0.5 – 1 mg/ml, aliquoted and frozen at -80 oC. Total protein 
concentration (mg/ml) was calculated using a DC Protein Assay (BIO-RAD).  
 
2.5.9. Protein Expression Levels - HEK293 cell membranes expressing β2-AR control or β2-
AR-s-peptide sensors were collected 24 h post transfection. Samples were treated with PNGase F 
and Endo H (3 h at room temperature) to remove β2-AR glycosylation sites. Supernatant (S) and 
pellet (P; containing membranes) were separated on 4-15% gradient polyacrylamide/SDS gel. 
Concentration (mol/mg) of sensor was assessed by loading mCitrine concentration standards 
alongside a known concentration (mg/mL) of membranes expressing β2-AR control sensor on a 
SDS-PAGE. Gels were scanned for fluorescence on a Typhoon Gel Imager (GE Healthcare) by 
exciting mCit at 488 nm and scanned at 520 nm BP 40. 
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2.5.10. Western Blotting – Membranes expressing indicated sensor were prepared as described 
above. Briefly, membranes were separated on 10% polyacrylamide/SDS gels and scanned for 
fluorescence on a Typhoon Gel Imager (GE Healthcare) before being transferred to PVDF 
membranes for 3 hours at 300 mA. Blots were blocked with 5% milk/TBST for 1 hour. Primary 
Gαs antibody (N-terminal; sc-823, Santa Cruz Biotechnology, Inc) or Gαq antibody (N-
terminal; sc-393, Santa Cruz Biotechnology, Inc) were used at a concentration of 1:1000 in 2% 
BSA/TBST and incubated overnight at 4°C. Blots were washed with TBST (3x 10 min) before 
addition of secondary antibody (goat anti-rabbit (Jackson ImmunoResearch), 1:2000 in 5% 
milk/TBST) and incubated at room temperature for 1 hour. Blots were washed again with TBST 
(3x 10 min) and developed using Immobilon Western Chemiluminescent HRP Substrate 
(Millipore). Blots were either imaged using film or using a ChemiDoc-it Imaging system (UVP) 
with no discernable difference in quality of signal.  
 
2.5.11. Radio-ligand assays – Radioligand assays follow previously published protocols (29). 
Bmax values were estimated by incubation of 2.5, 5, and 10 µg of membrane with 5 nM [3H]-
dihydroalprenolol ([3H]-DHA; PerkinElmer) for 90 min at room temperature in Tris-Buffered-
Saline (TBS) pH 7.4. Samples were transferred to GF/C membranes pre-treated with 0.3% 
polyethylenimine solution in TBS, washed extensively with TBS, treated with scintillation liquid 
(Microscint0; PerkinElmer), followed by measurement of radioactivity using a 96-well 
scintillation counter (TopCount, PerkinElmer). Non-specific binding was estimated with 10 µM 
propranolol treatment and was < 1% of total binding. Dissociation constant (Kd) of [3H]-DHA 
binding was determined by incubation of 10 pM (10 fmol/ml) of receptor with increasing 
concentrations of [3H]-DHA. Kd of [3H]-DHA binding was ~ 0.2 nM for wild-type, D130N and 
R131A β2-AR-no-pep sensors. Competitive inhibition (Ki) was assessed by incubation of 10 pM 
of receptor with increasing concentrations of isoproterenol (ISO), ICI118,551 (ICI) or buffer 
blank with 5 nM [3H]-DHA for 90 min at room temperature. Radioactivity in samples for Kd and 
Ki experiments was measured as described above. Non-specific binding in all instances was 
found to be <1%. Each experiment was done at least twice with different membrane 
preparations, with three separate samples prepared per condition, per experiment. 
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2.5.12. 35S-GTPγS binding assays – Radio-labeled GTPγS assays follow previously published 
procedures (28,30). Briefly, 60 fmol of wild-type or mutant (D130N or R131A) β2-AR-no-pep 
sensor expressing membranes (14–33 µg of membrane; receptor amounts determined by radio-
ligand Bmax binding as described above) were incubated in Buffer C (20 mM HEPES pH 7.4, 
100 mM NaCl, 5 mM MgCl2, 0.1 mM DTT, 100 µM GDP, 0.02% ascorbic acid) for 10 min at 
room temperature, followed by incubation with 10 µM ICI118,551 or buffer control for 10 min. 
Membranes were treated with 1 nM 35S-GTPγS (PerkinElmer) for 60 min at room temperature, 
followed by assessment of membrane radioactivity levels as described above. GDP concentration 
and incubation times used were empirically determined to provide the largest specific binding to 
14 µg of membrane expressing wild-type sensor (β2-AR-no-pep) relative to equal amount of 
untransfected membrane protein. Data are presented as difference between radioactivity counts 
(counts per minute) between untreated and ICI treated membranes. The experiment was repeated 
three times, with different membrane preparations, and involves three separate samples in each 
experiment. 
 
2.5.13. Statistical Analysis - Results are expressed as mean values ± s.e.m of at least three 
independent experiments with at least six repeats per condition. Statistical analysis was carried 
out using GraphPad Prism 5.0c (Graphad Software Inc.) Statistical significance was evaluated 
using Student’s paired t-tests performed are indicated in the figure legends with corresponding p-
values of *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Briefly, statistical significance was calculated 
using Student’s paired t-test comparing samples to respective no-pep sensor (see Methods, 
Molecular Cloning) for FRET ratio measurements or to matched untreated condition for ΔFRET 
measurements. Sigmoidal curves from concentration-response experiments were analyzed using 
non-linear regression curve fitting using log(agonist or inhibitor) vs. response (three parameters).  
Each condition was repeated at least 6 times, and each experiment was independently conducted 
at least 3 times (n ≥ 18). 
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2.7. Figures  
 
Fig. 2.1: FRET-based SPASM sensors for opsin and β2-AR are intact and functional.  SPASM 
sensor design: (a) Schematics of the GPCR-Gα c-terminal peptide sensors (left); sensor in the inactive 
(middle) and active (right) conformation. Protein domains were separated with Gly-Ser-Gly (GSG)4 
linkers to ensure rotational freedom. No-pep sensors do not contain the Gα c-terminus peptide. (b) Opsin-
t-mod and β2-AR-s-pep sensor localization to the plasma membrane in HEK293 live cells. (c) 
Fluorescence SDS-PAGE gel scans of HEK293 membranes expressing β2-AR no-pep or s-pep sensors. 
Intact membrane localization is witnessed by distinct 110 kDa bands in fractions containing membrane 
(P) but not supernatant (S). (d) cAMP levels in the presence or absence of agonist (100 µM isoproterenol) 
for untransfected (grey) or HEK293 cells expressing β2-AR-no-pep sensor (white). Specificity of agonist-
stimulated sensor response was verified by suppression with antagonists (150 µM metoprolol or 10 µM 
ICI118,551). Results are expressed as mean ± s.e.m. ***P < 0.001; n > 10. 
  




Fig. 2.2: Influence of endogenous Gα  levels on sensor 
FRET measurements. (a-b) β2-AR sensors are expressed at 
least five-fold in excess of three endogenous Gα subtypes 
(s/i/q). (a) Fluorescence SDS-PAGE gel scans of HEK293 
membranes expressing β2-AR-Gαs fusion sensor. (b) 
HEK293 membranes expressing the β2-AR-Gα fusion 
sensors were digested with TEV-protease to cleave a site 
between β2-AR-mCit and ER/K-α-helix-mCer-Gα. 
Membranes were separated by SDS/polyacrylamide gel 
electrophoresis, transferred onto PVDF membranes, and 
probed with anti-Gαs (sc-823; 1:1000), anti-Gαq antibody 
(sc-393; 1:1000) or anti-Gαi2 antibody (sc-13534; 1:200). 
Intact Gα expression is witnessed by distinct 80, 76 and 75 
kDa bands for TEV-digested Gαs, Gαq and Gαi2 fusion 
sensors respectively. (c-d) FRET ratios (mCit/mCer; 
525nm/475nm) of the β2-AR-s-pep sensor co-expressed with 
unlabeled (dark) (c) Gαs or (d) Gαq. Ratio of plasmid DNA 
of β2-AR-s-pep:Gα used for the transfections is indicated 
along abscissa (at least 5-fold over-expression of indicated 
Gα compared to endogenous Gα by densitometry). (Bottom 
panels) Immunoblots of membranes transfected with plasmid 
DNA at indicated ratios probed with (c) anti-Gαs or (d) anti-
Gαq antibodies. 
  




Fig. 2.3: Gα c-terminus peptide specifically binds to the active conformation of GPCRs in live 
HEK293 cells. (a) Schematics of the GPCR-Gα c-terminal peptide sensors (top); crystal structures of β2-
AR in the inactive (middle; PDB: 3NY8) and active (bottom; PDB: 3SN6) conformation. Gαs c-terminus 
(s-pep; red) binds to the active β2-AR conformation induced via stimulation with agonist. (b-j) 
GPCR/condition specified at top left and sensor abbreviation along abscissa. (b) Change in FRET ratio 
following agonist (9-cis-retinal + light) treatment for opsin-pep sensors. FRET spectra (430 nm mCer 
excitation) normalized to mCer emission (475 nm) for (c) β2-AR-s-pep, (d) β2-AR-i-pep sensors for 
samples treated with or without agonist (isoproterenol). (e-f) Change in FRET ratio following agonist 
(isoproterenol) treatment for β2-AR-pep sensors. (f) Dose-dependent inhibition of FRET with inverse 
agonist (ICI118,551; grey line). (g) Basal cAMP levels for β2-AR-no-pep sensors expressing the 
constitutively active β2-AR mutants (CAM, L272A). (h) FRET spectra (430 nm mCer excitation) 
normalized to mCer emission (475 nm) for wild-type (WT; black) and a constitutively active mutant 
(CAM; green) β2-AR-s-pep sensor (h) Gain in FRET following induction of constitutively active 
mutations (CAM, L272A) for β2-AR-s-pep sensors. (i) Scatter-plot of individual FRET ratio 
measurements (open circles) for indicated β2-AR-pep sensors/conditions derived from three independent 
experiments (colored red, green and blue), collected on three different days. Results are expressed as 
mean ± s.e.m. ***P < 0.001; n > 18. 
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Fig. 2.4: Mutagenesis of E/DRY motif interactions in β2-AR induces an active conformation. (a) 
Crystal structures of β2-AR in the inactive (top; PDB: 3NY8) and active (bottom; PDB: 3SN6) 
conformation. (Top) In the inactive state, the DRY motif residues in β2-AR display electrostatic 
interactions formed between R131 (blue) and D130/E268 residues (red). (Bottom) Indicated residues 
move apart following β2-AR activation. (b-e) GPCR/condition specified at top left and sensor 
abbreviation along abscissa. cAMP levels of HEK293 cells expressing wild-type (no-pep) for the 
indicated E/DRY mutant β2-AR-no-pep sensor in the (b) absence or (c) presence of agonist (100 µM 
isoproterenol). (d) FRET ratios (mCit/mCer; 525nm/475nm) of β2-AR E/DRY motif single and double 
(D/E: D130N+E268N) mutant s-pep sensors. (e) Change in FRET following agonist (100 µM 
isoproterenol) treatment of E/DRY mutant β2-AR-s-pep sensors. (f) The affinity for agonist 
(isoproterenol) was measured for wild-type (WT), D130N, and R131A β2-AR-no-pep sensors by 
competitive inhibition of [3H]-dihydroalprenolol ([3H]-DHA) binding. Results are expressed as percent of 
radio-ligand bound in the absence of competitor.  (g) Change in 35S-GTPγS binding induced by 10 µM of 
inverse agonist ICI118,551 for wild-type (WT), D130N, and R131A β2-AR-no-pep sensors. (h) 
Competitive displacement of [3H]-dihydroalprenolol binding by ICI118,551 for WT, D130N, and R131A 
β2-AR-no-pep sensors. Results are expressed as mean ± s.e.m of three independent experiments 
performed in triplicate. *P < 0.05, ***P < 0.001; n > 18 
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Fig. 2.5: Opsin-specific interactions centered on residue K296 are both necessary and sufficient to 
stabilize an inactive conformation. (a) Electrostatic interactions formed by the E/DRY motif are 
indicated on the crystal structure of inactive, dark rhodopsin (opsin + 9-cis-retinal; PDB: 1GZM). (b-f) 
GPCR/condition specified at top left and sensor abbreviation along abscissa. (b-c) FRET ratios 
(mCit/mCer; 525nm/475nm) of (b) basal (untreated) and (c) change in FRET following retinal addition 
and photo-activation of opsin’s E/DRY motif mutant t-mod sensors. (d) Retinitis pigmentosa (RP) 
inducing constitutively active opsin mutations and their interactions are indicated in the inactive dark 
rhodopsin crystal structure (PDB: 1GZM). (e-f) FRET ratios (mCit/mCer; 525nm/475nm) of (e) untreated 
(basal) and (f) change in FRET following retinal addition and photo-activation of opsin’s RP mutant t-
mod sensors. Results are expressed as mean ± s.e.m. **P < 0.01, ***P < 0.001; n > 18.  
  




Fig. 2.6: Inverse agonist ICI118,551 requires a functional E/DRY motif to suppress β2-AR basal 
activity. (a) Electrostatic interactions formed by the E/DRY motif are indicated on the crystal structure 
of β2-AR bound to inverse agonist (ICI118,551) (PDB: 3NY8). (b) Change in FRET following inverse 
agonists (10 µM ICI118,551 or 150 µM metoprolol) treatment of indicated E/DRY motif mutant β2-AR-
s-pep sensors. (c) ICI118,551 induced percent cAMP inhibition of HEK293 cells expressing wild-type 
(no-pep) or the indicated E/DRY motif mutant β2-AR-no-pep sensors. Results are expressed as mean ± 
s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001; n > 18. 
  




Fig. 2.7: Sensors detect stabilization of Gi conformations in β2-AR stimulated with metoprolol. 
Change in FRET following treatment of indicated β2-AR-pep sensors with (a) inverse agonist (150 µM 
metoprolol) or (b) with varying concentration of metoprolol. (c) Percent inhibition of 100 µM 
isoproterenol or 10 µM forskolin induced cAMP levels with 150 µM metoprolol or 10 µM ICI118,551, in 
PTX treated or untreated HEK293T cells expressing β2-AR-no-pep sensor. Results are expressed as mean 
± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001; n >18. 
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Fig. 2.8: Distinct structural 
mechanisms of β2-AR 
agonists and inverse 
agonists. In the absence of 
ligand (basal state), only a 
small proportion of the β2-AR 
population adopts Gs 
conformations. Isoproterenol 
(agonist) treatment 
destabilizes the DRY ionic-
lock and enhances interaction 
with the Gαs c-terminus, 
resulting in activation of 
adenylyl cyclase (AC). 
Conversely, ICI118,551 
(inverse agonist), reinforces 
the DRY ionic-lock, and shifts 
the equilibrium toward 
inactive conformations. 
Biased agonist (metoprolol) 
stabilizes Gi conformations, 
promoting Gi dependent 
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ER/K linked GPCR-G protein fusions systematically modulate 
second messenger response in cells 
Rabia U. Malik, Michael Ritt, Roger K. Sunahara, and Sivaraj Sivaramakrishnan 
 
3.1 Abstract 
FRET or BRET approaches are well established for detecting ligand induced GPCR-G protein 
interactions in cells. However, current FRET/BRET assays rely on co-expression of GPCR and 
G protein, and hence depend on the stoichiometry and expression levels of the donor and 
acceptor probes. On the other hand, GPCR-G protein fusions have been used extensively to 
understand the selectivity of GPCR signaling pathways. However, the signaling properties of 
fusion proteins are not consistent across GPCRs. In this study, we describe novel sensors based 
on the Systematic Protein Affinity Strength Modulation (SPASM) technique. Sensors consist of 
a GPCR and G protein tethered by an ER/K linker flanked by FRET probes. SPASM sensors are 
tested for the β2-, α1-, and α2- adrenergic receptors, and adenosine type 1 receptor (A1R), 
tethered to Gαs-XL, Gαi1, or Gαq subunits. Agonist stimulation of β2-AR and α2-AR increases 
FRET signal comparable to co-expressed FRET/BRET sensors. SPASM sensors retain signaling 
through the endogenous G protein milieu. Importantly, ER/K linker length systematically tunes 
the GPCR-G protein interaction, with consequent modulation of second messenger signaling for 
cognate interactions. SPASM GPCR sensors serve the dual purpose of detecting agonist-induced 
changes in GPCR-G protein interactions, and linking these changes to downstream signaling.  
 
3.2 Introduction 
G protein coupled receptors relay detection of stimuli such as photons, neurotransmitters, 
hormones, or drugs from the extracellular milieu to the intracellular environment by binding and 
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activating one or more functionally distinct heterotrimeric G proteins1. Coupling between an 
active GPCR and G proteins stimulates accumulation of second messengers such as cyclic AMP, 
calcium/potassium ions, and inositol phosphate1. Efforts to monitor and understand the link 
between GPCR-G protein interactions and downstream second messenger response are 
complicated by the range of cellular factors that influence GPCR signaling including the relative 
localization and abundance (concentration) of GPCR and G proteins, regulatory proteins such as 
Regulators of G protein signaling (GRS), G protein kinases (GRKs), and non-G protein effectors 
such as β-arrestins2. 
Current approaches to visualize GPCR-G protein interaction in cells involve probing the 
interaction between individually expressed fluorescent or luminescent protein fusions using 
fluorescence/bioluminescence resonance energy transfer (FRET/BRET)3-7. Therefore, insights 
into the GPCR-G protein interaction gained from these studies are limited by their dependence 
on the relative concentration and co-localization of individually expressed GPCR and G protein. 
Alternatively, direct GPCR-G protein fusions generated by tethering the N-terminus of the Gα to 
the GPCR’s C-tail with a short or no linker in between have been used to study the influence of 
tethering different G protein subunits on G protein activation and second messenger signaling8,9. 
Such fusions have not been used to monitor the GPCR-G protein interaction using resonance 
energy transfer approaches6. A limitation of direct fusions is that GPCRs with short C-tails do 
not efficiently signal to the tethered G protein10-13.  
In this study, we combine the strengths of FRET and fusion proteins by leveraging the 
Systematic Protein Affinity Strength Modulation (SPASM) approach14,15. SPASM involves 
expression of a single polypeptide encoding a GPCR tethered to a G protein via an ER/K α-
helix/linker that is flanked by a pair of FRET probes (mCitrine (FRET acceptor) and mCerulean 
(FRET donor) (Fig. 3.1a). Unstructured (Gly-Ser-Gly)4 linkers are inserted in between each 
component to provide rotational flexibility (Fig. 3.1a). Similar to GPCR fusions, GPCR SPASM 
sensors enable control over GPCR-G protein stoichiometry and co-localization. ER/K linkers 
with end-to-end distance of 10-30 nm (measured along the α-helical backbone) are designed to 
provide adequate separation between the GPCR (~ 3 nm) and the G protein (~ 5 nm)14,16. 
Increasing ER/K linker length from 10-30 nm has been shown to systematically decrease the 
effective concentration of the protein-protein interaction14,15,17,18. We have previously reported on 
SPASM sensors involving individual fusions of GPCRs with the C-terminal peptide of the Gα 
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subunit19-21. Here, we describe SPASM GPCR sensors with the entire Gα subunit that can bridge 
the gap between the GPCR-G protein interaction and downstream signaling10-13. 
In this proof-of-concept study, SPASM sensors are made for four GPCRs with varying C-tail 
lengths (8-87 amino acids). The β2-adrenergic receptor (β2-AR), α2-adrenergic receptor (α2-
AR), α1-adrenergic receptor (α1-AR), and adenosine type 1 receptor (A1R) are each tethered to 
two functionally distinct Gα subunits (Gαs-XL, Gαi1, and Gαq). Consistent with literature 
reports of co-expressed GPCR-G protein sensors3,5, we find SPASM sensors with cognate 
GPCR-G protein pairs show enhanced interaction following agonist stimulation as indicted by a 
gain in FRET signal. Varying ER/K linker length from 10 nm to 30 nm systematically tunes the 
basal interaction between tethered GPCR-G protein pairs. However it only modulates second 
messenger response from select GPCR-G protein pairs over and above endogenous levels. 
Together, these features of the SPASM GPCR-G protein sensors facilitate both the detection of 
GPCR-G protein interactions in cells and establish their link to downstream signaling pathway. 
 
3.3. Results 
3.3.1. Integrity of GPCR-G protein fusions – The GPCR and Gα subunit were expressed as a 
single polypeptide fusion with a SPASM module between them (Fig. 3.1a). All individual 
protein elements are separated by (Gly-Ser-Gly)4 linkers to provide rotational flexibility (Fig. 
3.1a). The SPASM module provides 1:1 stoichiometry of GPCR-Gα expression and consists of 
an ER/K α-helical linker flanked by a FRET pair (mCerulean/mCitrine)14. FRET probes enable 
monitoring of cellular expression and sensor integrity. Fusions lacking a G protein (–) served as 
controls to assess background signaling through endogenous G proteins. Together, these sensor 
properties facilitate pairwise comparison across fusions at matched cellular expression levels 
(see Methods). GPCR-G protein fusions were initially generated for the prototypical β2 
adrenergic receptor (β2-AR). Fusions are expressed primarily >80% at the plasma membrane of 
HEK293T cells (Fig. 3.1b), are intact as assessed by immuno-blotting membrane preparations 
(Fig. 3.1c), and bind Gβγ subunits to equal extents (Fig. 3.1d). Consistent with the known basal 
activity of this GPCR, over-expression of β2-AR (1-2 pmol/mg total protein) elevates basal 
cAMP levels relative to the untransfected (UN) cells (Fig. 3.1e)22. Treatment with the inverse 
agonist metoprolol (Meto) significantly attenuates the enhanced cAMP levels, attesting to the 
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role of exogenously expressed β2-AR (Fig. 3.1e). The functionality of Gs in the β2-AR-Gs 
fusion protein is consistent with ~5-fold increase in basal cAMP levels as compared to sensors 
expressing β2-AR alone (–) (Fig. 3.1e). 
 
3.3.2. Agonists modulate fusion interaction and downstream response – In agreement with 
previous β2-AR-Gs fusions23,24, tethering β2-AR to Gs with a 10 nm ER/K linker enhances both 
efficacy (Fig. 3.2a) and potency (β2-AR-Gs EC50 = 0.09 ± 0.05 nM; β2-AR EC50 = 0.44 ± 0.3 
nM; Fig. 3.2b) of the isoproterenol induced cAMP levels compared to over-expression of β2-AR 
alone (–). Likewise, epinephrine treatment results in a greater loss in cAMP signaling for ER/K 
linked α2-AR-Gi compared to α2-AR alone (–) (Fig. 3.2c).  To test if agonist stimulation also 
enhances interaction between the cognate GPCR-G protein pair, changes in FRET ratio were 
examined. The SPASM module is designed to maintain low FRET levels in the absence of an 
interaction between the GPCR and G protein (dissociated state; Fig. 3.3a) 14. Interaction between 
the GPCR and G protein (associated state; Fig. 3.3a) should bring the FRET donor and acceptor 
in closer proximity, leading to higher FRET levels. In accordance with previous studies using co-
expressed GPCR and G protein FRET/BRET pair fusions, treatment with agonist (100 μM 
isoproterenol) results in a gain in FRET for the cognate β2-AR-Gs pairing3,4, but not for non-
cognate Gi, Gq, or fusions lacking a G protein (–) in live cells (Figs. 3b, left panel). Likewise, for 
the Gi coupled receptor, α2-AR, stimulation with 100 μM epinephrine induced a gain in FRET 
for Gi4,5, but not Gs or Gq (Fig. 3.3b, right panel). ΔFRET for β2-AR-Gs = 0.006 ± 0.001 and 
α2-A-Gi = 0.01 ± 0.002 are small but statistically significant. These changes are comparable to 
previously reported measurements using co-expressed sensors of β2-AR-Gs (ΔBRET ~ 0.025) 
and α2-AR-Gi (ΔFRET ~0.022)3-5,25. 
 
3.3.3. Fusions interact with endogenous G proteins – One concern with fusions is that the 
addition of the SPASM module at the C-tail of the GPCR may cause steric hindrance between 
GPCR interactions with the endogenous signaling machinery. The ER/K linked fusions are 
designed to spatially separate the GPCR and G protein in the absence of an interaction and 
should therefore freely permit interactions with non-tethered G proteins14,26. To test the ability of 
the ER/K linked fusions to interact with non-tethered G proteins in the cellular milieu, we 
focused on β2-AR and α1-AR interactions with Gs and Gq, as they influence distinct second 
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messengers (cAMP and IP1) and facilitate interpretation of downstream responses. First, an 
unlabeled (dark) Gα subunit was increasingly co-expressed relative to the ER/K linked fusions, 
and the FRET ratios were determined for equal levels of expression of the ER/K linked fusion 
(Fig. 3.4a). Elevated expression of Gs or Gq, relative to β2-AR-Gs or α1-AR-Gq sensors, 
respectively, systematically decreased FRET ratios attesting to interactions between cellular Gs 
or Gq and the GPCR in the ER/K linked fusions (Fig. 3.4b and c). Likewise, tethering the 
cognate G protein (Gs and Gq, respectively, for β2-AR and α1-AR) increases second messenger 
signaling through the cognate pathway (cAMP and IP1, respectively, for β2-AR and α1-AR), 
whereas, tethering to the non-cognate G protein (Gq and Gs, respectively, for β2-AR and α1-
AR) does not suppress signaling through endogenous G proteins (Fig. 3.4 d and e – no 
significant difference between sensors without G protein compared to those with non-cognate G 
protein). Together, these measurements demonstrate that while the ER/K linked G protein does 
interact with the GPCR, it does not measurably perturb interactions with endogenous 
components. 
 
3.3.4. ER/K linker length modulates second messenger signaling of cognate GPCR-G protein 
fusions – Previous studies show that increasing ER/K linker length from 10 to 30 nm decreases 
the effective concentration of the tethered proteins from 10 µM to 100 nM14. FRET ratios are 
sensitive to the distance between and concentration of acceptor and donor molecules6. As 
expected, FRET ratio measurements for matched sensor expression demonstrate that increasing 
ER/K linker length from 10 to 30 nm, systematically decreased basal FRET ratios for a range of 
both cognate and non-cognate GPCR-G protein interactions (Figs. 4 and 5; FRET ratios are 
depicted by open black circles; GPCR color indicates its cognate G protein). To test whether 
modulating the GPCR-G protein interaction within the ER/K linked fusion influences 
downstream signaling, the second messenger corresponding to the tethered G protein was 
measured under matched protein expression levels (Figs. 5 and 6; Filled circles with colors 
corresponding to the second messenger; red – cAMP; green – suppression of forskolin-
stimulated cAMP; blue – IP1). In correlation with the systematic changes in the relative GPCR-
Gx fusions interaction (FRET ratios), significant modulation of second messenger levels was 
observed only for cognate GPCR-G protein fusions (Figs. 5 and 6). Specifically, tethering β2-AR 
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(Gs coupled receptor) to Gs modulates cAMP (Fig. 3.5b), whereas tethering α1-AR (Gq coupled 
receptor) to Gq modulates IPx (Fig. 3.5d). In contrast, tethering β2-AR to Gq or α1-AR to Gs 
modulates the GPCR-Gx interaction (FRET ratio) but not IP1 or cAMP levels respectively (Figs. 
5 c and e). Tethering A1R (Gi coupled receptor) to Gi suppresses forskolin-stimulated cAMP 
levels, whereas tethering to Gs does not enhance cAMP (Figs. 6 b and c). Interestingly, α2-AR, 
which has been shown to couple to both Gs and Gi27, shows both enhanced cAMP upon tethering 
to Gs and suppression of forskolin-stimulated cAMP upon tethering to Gi (Figs. 6 d and e), 
unlike previously reported α2-AR fusions11. Together, these measurements support the ability of 




In this study, we describe a new approach that relies on ER/K-linked fusions15 to compare 
downstream signaling from different GPCR – G protein pairings. In contrast to previous GPCR-
G protein fusions that use a short unstructured linker9-11,13,23,28, in the absence of an interaction, the 
structured ER/K linker provides a significant spatial separation between the GPCR and the G 
protein fused to its ends. The ER/K linker has been previously characterized to exist primarily in 
an extended α-helical conformation, with end-to-end distances of ~ 7 to ~ 22 nm for 10 to 30 nm 
lengths along the α-helical backbone26. We show that SPASM sensors with GPCRs tethered to 
non-cognate G protein retain signaling through the endogenous pathways (Figs. 3.4 d and e). 
Likewise, sensors respond to increasing concentration of exogenously expressed unlabeled Gα 
subunits (Fig. 3.4 b and c). Hence, our data suggest that rather than enforce GPCR-G protein 
coupling9,13,23 or sterically hinder interactions with endogenous G proteins10,11,13 the SPASM 
sensors can progressively modulate signaling through the tethered G protein relative to 
endogenous levels. 
Unlike current FRET/BRET sensors that rely on the co-expression of labeled GPCR and G 
protein subunits3-7,29,30, the SPASM sensors require the expression of a single polypeptide that 
provides 1:1 stoichiometry between the exogenously expressed GPCR and G protein. Agonist 
stimulation provides changes in FRET (ΔFRET) comparable to those previously reported using 
co-expressed FRET/BRET pairs3-5. Hence, the SPASM sensors serve the dual purpose of probing 
	
 51 
agonist-stimulated changes in GPCR-G protein interaction while examining the downstream 
response using the same construct. 
ER/K linkers are designed to modulate the effective concentration of the intra-molecular 
interaction14,15, where the same linker length provides matched effective concentration across 
different GPCR-G protein pairings. However, given the localization of both GPCRs and G 
proteins on the plasma membrane, and the potential segregation of GPCRs into membrane 
micro-domains31, the measurements from any FRET/BRET based assay in live cells will have 
contributions from both intra-molecular interactions and those induced by the proximity of 
sensors on the plasma membrane32. Hence, measurements in each figure panel were performed 
with matched sensor expression, as determined by mCitrine fluorescence per unit cell density 
(see Methods). Nonetheless, the FRET ratio does decrease systematically with increasing ER/K 
linker length for all of the GPCR-G protein combinations tested suggesting that the ER/K linker 
does systematically alter the proximity between GPCR-G protein. In combination with the 
observed systematic decrease in the second messenger levels for cognate GPCR-G protein 
pairings our data suggest that the ER/K linker is able to modulate the effective concentration of 
the GPCR-G protein interaction. Importantly, for non-cognate GPCR-G protein pairings, while 
the FRET ratio does systematically decrease with ER/K linker length, we do not detect a 
significant change in non-cognate downstream signaling, attesting to the specificity of the 
downstream response. Hence, using varying length ER/K linkers is an effective approach to 
bridge the gap between GPCR-G protein interactions as detected by FRET and consequent 
downstream signaling as measured by second messenger levels.  
 
3.5. Experimental Procedures 
3.5.1. Reagents and buffers – fenoterol hydrobromide, fibronectin, guanosine 5′-diphosphate 
sodium salt  (GDP), 3-isobutyl-1-methylxanthine  (IBMX),  (-)-isoproterenol  (+)- bitartrate salt, 
and pertussis toxin from Bordetella pertussis  (PTX) were purchased from Sigma-Aldrich. n-
dodecyl-β-D-maltopyranoside, Anagrade (DDM) was bought from Anatrace. Purified Gαq (Mus 
musculus) Gαs-long (Rattus norvegicus) were obtained from Kerafast. Anti-Gαs/olf (SC383) 
and anti-Gβ antibody  (SC378) were purchased from Santa Cruz Biotechnology. Anti-pan Gα 
antibody (3992) and anti-HA antibody  (MMS-101p) were acquired from Cell Signaling 
Technology and Covance respectively. cDNAs for α1A-AR isoform 3  (Homo sapiens), and α2A-
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AR  (Sus scrofa) were kind gifts from Dr. Richard Neubig. cDNAs for human β2-AR, long 
splice variant of Gαs, Gαi2 isoform 1, and Gαq were purchased from GE  (Open Biosystems). 
Human A1R was acquired from DNASU Plasmid Repository. DNA transfection reagents X-
tremeGENE HP and Mirus-LT DNA were acquired from Roche and Mirus respectively. Buffer 
A is 20 mM HEPES, 5 mM KCl, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 0.2% dextrose  
(w/v), 1.5 μg mL-1 aprotinin and 1.5 μg mL-1 leupeptin at pH 7.45. Buffer B is 20 mM HEPES, 
0.5 mM EDTA, 5 mM MgCl2, 0.1 mM DTT, 10 μM GDP, 1.5 μg mL-1 aprotinin, 1.5 μg mL-1 
leupeptin and 50 μg mL-1 phenylmethanesulfonyl fluoride at pH 7.4. Buffer C is 20 mM HEPES, 
0.5% decaethylene glycol monododecyl ether  (C12E10), 100 mM NaCl, 1 mM MgCl2 10 mM 
GDP, 5.5 mM β-mercaptoethanol, 10 mg mL-1 phenylmethanesulfonyl fluoride at pH 8.0. 
 
3.5.2. Molecular cloning – PCR products for α1A-AR  (isoform 3), β2-AR, A1R, long splice 
variant of Gαs, Gαi2, and Gαq were obtained from human cDNA. For mammalian HEK293 
expression, all GPCR and Gα constructs were cloned into a PCDNA5/FRT vector. A modular 
scheme was designed for cloning of GPCR sensors. Each GPCR-G protein sensor contained 
from N- to C-terminus: a full length GPCR, mCitrine  (FRET acceptor), ER/K linker, mCerulean  
(FRET donor), and a Gα subunit. A  (Gly-Ser-Gly)4 linker was inserted between all protein 
domains as part of the primer sequence to allow for free rotation between domains. Control 
GPCR sensors  (–) did not contain a Gα subunit after mCerulean and instead had repeating  
(Gly-Ser-Gly)4 residues. All β2-AR-sensors also contained either an N-terminal HA-tag or a His-
tag. Finally, all constructs were confirmed by sequencing.  
 
3.5.3. Mammalian cell preparation and sensor expression – HEK293T-Flp-In  (HEK293T, 
Invitrogen) cells were cultured in DMEM supplemented with 10% FBS  (v/v), 4.5 g L-1 D-
glucose, 1% Glutamax, 20 mM HEPES, pH 7.5 at 37 oC in a humidified atmosphere at 5% CO2. 
HEK293T cells were plated into 6-wells tissue culture treated plates at ~30% confluence. Cells 
were transfected 16-20 h later with X-tremeGENE HP DNA transfection reagent. Transfection 
conditions including the amount of DNA  (1.4 – 4 µg DNA + 4.2 – 6 µl reagent) and the length 
of transfection  (control sensors: 18-24 h; Gα sensors: 22-32 h) were optimized to consistently 
yield equivalent levels of sensor expression across different conditions. For GPCR-G protein 
competition assays, 100 ng, 300 ng, or 1 μg of α1-AR-mCherry were co-transfected with 2 or 4 
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μg of indicated sensors. For all experiments sensor integrity, localization, and sensor expression 
per optical density  (O.D.) were tracked to ensure consistency. Experiments were conducted at 
60-80% transfection efficiency evaluated by 20x and 40x magnification on a Nikon tissue-
culture microscope enabled with fluorescence detection. Additionally, at the time of the 
experiment, 60-90% of transfected cells expressed predominately plasma membrane localized 
sensor with minimal localization to the intracellular compartments. Each experiment was 
performed at equivalent sensor expression and matched O.D. of the cell suspension using the 
following steps. First, cells were resuspended by gentle pipetting into their original media. Cells 
were then spun down  (300 g, 3 min) and washed once with Buffer A. Subsequently, cells were 
resuspended in an appropriate volume of Buffer A to reach a 0.3 O.D  (A600 nm, BioMate 3S 
Spectrophotometer, Thermo Scientific, 3 mm path-length, optical glass cuvette) for all 
fluorescence-based measurements. Finally, sensor expression was measured by mCitrine 
fluorescence. mCitrine fluorescence was held within 1.6-2.4x106 counts-per-second  (c.p.s) for a 
cell O.D of 0.3. For each experiment, sensor integrity was tracked by measuring the mCitrine  
(excitation 490 bandpass 8 nm; emission range 500-600 bandpass 4 nm; emission maximum 525 
nm) to mCerulean fluorescence ratio  (excitation 430 bandpass 8 nm; emission range 450-600 
bandpass 4 nm; emission maximum 475 nm). As part of the sensor design, mCitrine and 
mCerulean label the C-terminus of GPCR and N-terminus of Gα subunit respectively. All 
experiments were conducted at mCitrine to mCerulean fluorescence ratio of 1.7-2.1. Similarly, 
mCherry fluorescence was recorded to evaluate α1-AR-mCherry expression for a cell O.D of 
0.3.  
 
3.5.4. Live cell microscopy and image analysis – HEK293T cells were plated  (~15-20% 
confluence) on 35 mm glass bottom dishes  (MatTek Corp) coated with 10 mg mL-1 fibronectin. 
14-16 h after plating  (30-40% confluence), cells were transfected with Mirus-LT or 
XtremeGENE HP DNA transfection reagent. 16-22 h post-transfection cells were washed three 
times with Buffer A  (37 oC) to remove excess phenol red from the media. Cells were 
subsequently imaged for no more than 30 min in Buffer A media. Cell images were collected at 
60x magnification using a Nikon TiE microscope equipped with a mercury arc lamp, 60x and 
100x 1.4 Numerical Aperture Plan-Apo oil objectives and with an Evolve 512x512 EM-Charge-
Coupled-Device camera  (Photometrics).  Z-stack images were taken with 1 μm steps and the 
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resultant stack of images was deconvolved using AutoQuantX software. Membrane expression in 
images was analyzed in ImageJ (NIH) using the threshold and measure tools to select and 
quantify membrane expression compared to internal localization (Fig. 3.7). 
 
3.5.5. Fluorescence measurements – Using FluoroMax-4 fluorometer  (Horiba Scientific), FRET 
spectra were generated by exciting cells at 430 nm  (bandpass 8 nm) in an optical glass cuvette  
(3-3.30-SOG-3, Starna Cells Inc.). Emission was scanned from 450-600 nm  (bandpass 4 nm). 
For mCitrine-only measurements, cells were exited at 490 nm  (band pass 8 nm), and emission 
was recorded from 500-600 nm  (bandpass 4 nm), emission maximum was set at 525 nm. For 
mCherry expression, cells were excited at 570 nm with an 8 nm bandpass; emission was 
collected from 600 – 700 nm at 4 nm bandpass. Where indicated, maximum emission value at 
610 nm is reported as an estimate of α1-AR-mCherry expression in HEK293T cells. For TR-
FRET experiments, eGFP emission maxima at 510 nm was measured by exciting at 480 nm band 
pass 8 nm, and recording emission from 500-600 nm band pass 4 nm.  
 
3.5.6. Live cell FRET calculations – FRET measurements were conducted at matched O.D. in 
Buffer A. Untransfected and transfected cells were resuspended in Buffer A at 0.3 O.D. To 
correct for scattering, FRET emission spectrum of an untransfected cell suspension, at equivalent 
O.D, was subtracted from FRET spectrum of the transfected cell suspension.  The corrected 
FRET emission spectra were normalized to mCerulean emission  (475 nm).  FRET ratio was then 
calculated by dividing mCitrine emission  (525 nm) by the mCerulean emission  (475 nm).  
 
3.5.7. ΔFRET experiment – Live cell ΔFRET experiments were conducted as previously 
described 21. Briefly, cells were prepared and re-suspended into pre-warm Buffer A. 90 μL 
aliquots of cells were added into eppendorf tubes placed in a 37oC water bath. Samples were 
treated with buffer control or indicated ligand for 3 or 5 min at 37oC. Separate and clean cuvettes 
were used to collect FRET spectra for treated and untreated samples to prevent cross-
contamination.  
 
3.5.8. Sensor purification from HEK293 cells – For anti-Gβ experiments, purification of His tag-
β2-AR-G protein and control  (–) sensors from HEK293T cells followed the previously 
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published protocol 16.  Frozen membranes were thawed quickly to room temperature and briefly 
re-homogenized with a rotary pestle. 5% cholate buffer  (5% sodium cholate in 50 mM HEPES, 
3 mM MgCl2, 50 mM NaCl with 1 μg mL-1 aprotinin, 1 μg mL-1 leupeptin, 10 μg mL-1 
phenylmethanesulfonyl fluoride, and 5.5 mM β-mercaptoethanol, pH 8.0) was added to a final 
concentration of 1% cholate. This mixture was incubated on ice for 45 min and separated by 
ultracentrifugation at ~105,000 g for 40 min at 4 oC. The supernatant was harvested and diluted 
drop wise with four volumes of Buffer C to one volume of supernatant, and was pipetted gently 
to mix. The diluted supernatant was added to nickel-NTA resin  (Qiagen) and incubated 30 min 
at 4 oC with rotation. The resin was washed 3x with 500 μL Buffer C + 5 mM imidazole. The 
final wash was removed and the resin was brought to room temperature and eluted for 3-5 min 
with 150 μL of elution buffer  (Buffer C + 200 mM imidazole).  The eluted resin was spun down, 
the supernatant harvested, and measured for mCerulean and mCitrine fluorescence in a 
fluorometer  (as described above).  Samples were stored in SDS laemmli sample buffer at -80 oC.   
 
3.5.9. Western blot – For anti-HA western blot, 20 μg of membranes containing β2-AR-Gs 
sensor were boiled in Buffer B supplemented with Glycoprotein Denaturing Buffer  (NEB) at 95o 
C for 5 min. Boiled samples were subsequently treated with 500 units of PNGase F  (NEB) for 
three hours at 37 oC. For anti-Gβ, equivalent amount of sensors, as measured by mCitrine 
fluorescence, were loaded on SDS-PAGE Gels  (10% polyacrylamide). Gels were imaged for 
mCitrine fluorescence  (excitation 488 nm, emission 520 nm, bandpass 40 nm) using a Typhoon 
Gel Imager  (GE Healthcare). Gels were transferred to PVDF membranes for three hours at 300 
mA. Anti-HA and anti-Gβ were blocked with 2% milk/TRIS-buffered saline with 1% Tween  
(TBST) for either one hour at room temperature or 4 oC overnight. Blots were then incubated 
with indicated primary antibody at a 1:1,000 dilution in 5% milk/TBST. For the anti-Gβ 
experiment, blots were washed with TBST, and incubated with 1:5,000 or 1:10,000 horseradish 
peroxidase  (HRP) conjugated goat anti-rabbit IgG secondary antibody  (0031460, Fisher 
Scientific) in 5% milk/TBST or 5% BSA/TBST for one hour at room temperature. Similarly for 
anti-HA experiments, blots were incubated with 1:10,000 Sheep anti-mouse HRP conjugated 
secondary antibody  (GE Healthcare, NA931). All blots were developed with Immobilon 
Western Chemiluminescent HRP Substrate  (Millipore). Blots were imaged using a ChemiDoc-It 




3.5.10. cAMP assays – 28-32 h post transfection  (XtremeGENE HP) HEK293T cells expressing 
indicated sensor were harvested to assess cAMP levels using the bioluminescent cAMP Glo 
assay  (Promega). Cells were gently suspended in their original media, were counted using a 
hemocytometer, and spun down  (300 g, 3 min). Appropriate volume of buffer  (PBS 
supplemented with 800 μM ascorbic acid and 0.2% dextrose  (w/v)) was added to reach 2x106 
cells mL-1 density for basal experiments or 4x106 cells mL-1 density for ligand based assays. Cell 
suspensions were aliquoted into 96 wells round-bottom opaque plates. Cells were treated without 
ligand in the presence of 0.25 mM IBMX for 15 min at 37 oC or with 100 μM isoproterenol for 3 
min at room temperature. For cAMP suppression assays, cells were treated with 1 μM forskolin 
and with or without ligand for 15 min at 37 oC. Subsequently, cells were lysed and the protocol 
was followed according to the manufacturer’s recommendation  (Promega). Luminescence was 
measured using a microplate luminometer reader  (SpectraMax M5e, Molecular Devices).  
cAMP levels  (relative luminescence unit, RLU) were evaluated by subtracting the untransfected 
background from the transfected conditions. Each experiment had four technical repeats per 
condition and was independently repeated at least three times  (N > 3).   
 
3.5.11. IP1 assays – 28-32 h post transfection  (XtremeGENE HP) HEK293T cells expressing the 
indicated sensor were harvested to assess IP1 levels using the IP-One HTRF assay kit  (Cisbio). 
Cells were gently suspended in their original media, counted using a hemocytometer, and spun 
down  (300 g, 3 min). An appropriate volume of StimB buffer  (CisBio: 10 mM Hepes, 1 mM 
CaCl2, 0.5 mM MgCl2 , 4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose, 50 mM LiCl, pH 7.4) was 
added to reach 3x106 cells mL-1 density. Cells were incubated at 37 oC for 15 min. The 
manufacturer’s protocol was modified in order to achieve a high signal to noise ratio. 150 μL of 
suspension was incubated for one hour with 30 μL of lysis buffer  (Cisbio), 54 μL StimB buffer, 
6 μL IP1 conjugated to d2 dye, and 6 μL terbium cryptate-labeled anti-IP1 monoclonal antibody. 
IP1 FRET spectra were collected by exciting samples at 340 nm  (bandpass 15 nm). Emission 
counts were recorded from 600-700 nm  (bandpass 10 nm) using a long pass 475 nm filter  (FSQ 
GG475, Newport). Raw IP1 signal was calculated from the 665 nm to 620 nm ratio. Basal IP1 
signal was corrected by subtracting the untransfected IP1 ratio from cells expressing transfected 
sensor. For ligand experiments, data are presented as a change in raw IP1 ratio following drug 
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treatment.  Each experiment had four repeats per condition and was independently repeated at 
least three times  (N > 3).   
 
3.5.12. Statistical Analysis – Data are expressed as mean values ± S.E.M. Experiments were 
independently conducted at least three times, with 3-6 technical repeats per condition  (N > 3). 
Statistical analysis was performed using GraphPad Prism 6.0c  (Graphpad Software, Inc.) 
Statistical significance was performed for individual experiments using paired Student’s t-test. 
To assess how the data varied across experimental repeats, data were pooled and paired or 
unpaired Student’s t-tests were conducted to evaluate significance. Where indicated, p-values *, 
p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
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3.7. Figures  
 
Fig. 3.1: GPCR-G protein fusion sensors are intact and functional. (a) Schematic of the GPCR-G 
protein sensor design. Protein domains are separated by (GSG)4 linkers to ensure rotational freedom.  
Control (–) sensors do not contain a Gα subunit. (b) Sensors localize to the plasma membrane in live 
HEK293T cells as shown in representative images. (c) Western blot of membranes expressing HA-β2-
AR-Gαs probed with anti-HA antibody. A distinct 150 kDa band indicates intact sensor expression. (d) 
Membranes expressing HA-β2-AR-Gαx sensors were subjected to HA-affinity purification and probed 
with anti-Gβ antibody. Equivalent amount of sensor is loaded per lane as assessed by mCitrine 
fluorescence. Gβ associates with the Gαs, Gαi, or Gαq subunit. (e) cAMP production in the presence or 
absence of inverse agonist (100 μM metoprolol) for β2-AR  tethered with or without Gs. Untransfected 
HEK293T cells (UN) are not transfected with any sensor. Data are derived from at least three independent 
experiments, with at least three replicates per condition. Data are represented as % no-G protein control (–









Fig. 3.2: Agonist enhances downstream second messenger response via the fused G protein. (a) 
cAMP production in the presence of (a) saturating (100 μM) or (b) varying concentration of isoproterenol 
for β2-AR  tethered with or without (-) Gs. (b) Data are represented as percent maximum cAMP levels for 
100 μM isoproterenol treatment of β2-AR fusions tethered with or without (-) Gs. (c) Percent inhibition 
of 1 μM forskolin induced cAMP production for α2-AR fusions with or without Gi treated with 100 μM 
epinephrine. Data are derived from at least three independent experiments, with at least three replicates 




































































Fig. 3.3: Agonist modulates cognate GPCR-Gx fusion interactions. Schematic of the GPCR-G protein 
fusions linked with the 10 nm ER/K linker in the associated (high FRET) and dissociated (low FRET) 
states in live cells. GPCRs are colored by their cognate G proteins; red and green indicate Gs (β2-AR) 
and Gi  (α2-AR) coupled receptors respectively. (b) Change in FRET (ΔFRET) for indicated GPCR-Gx 
fusions following agonist treatment in live cells (100 μM isoproterenol (ISO), 1 mM epinephrine (EPI). 
Data are derived from at least three independent experiments, with at least three replicates per condition 
(mean ± S.E.M. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001). For additional statistical 
analysis see Tables 3.1 and 3.2. 
 
  





























Fig. 3.4: Fusions modulate GPCR-G protein signaling relative to the endogenous cellular 
environment. (a) Schematic of competitive binding of un-tethered Gx (‘dark Gx’) to GPCR-Gx fusions. 
(b and c) FRET Ratios (525 nm/475 nm) for cells expressing GPCR-Gx fusion and cognate Gx after 
transient co-transfection with different concentrations of dark Gx DNA (0, 2, and 4 μg well-1). GPCR-Gx 
fusion DNA (2-4 μg well-1) was optimized to maintain equivalent expression across conditions. FRET 
Ratios for cells co-expressing (b) β2-AR-Gs fusions with unlabeled dark Gs (red) or  (c) α1-AR-Gq 
fusions with dark Gq (blue). (d) Basal cAMP and levels (e) IP1 for cells expressing (d) β2-AR and (e) α1-
AR tethered to Gs, Gq, or no G protein  (–).  (b-e) Data are derived from at least three independent 
experiments, with at least three replicates per condition (mean ± S.E.M. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 
0.001; ****, p ≤ 0.0001).  
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Fig. 3.5: ER/K linker length specifically modulates basal β2-AR-Gs and α1-AR-Gq downstream 
response in live cells. (a) Schematic of the GPCR-G protein fusions. Color represents cognate GPCR-G 
protein pair and corresponding downstream response (red: β2-AR, Gs, and cAMP levels; blue: α1-AR, 
Gq, and IP1 signal). (b-e) Fusion type is indicated on the top left. FRET Ratios (525 nm/475 nm; open 
black circles, right y-axis) and basal (ligand-free) downstream response (filled colored circles, left y-axis) 
are compared to ER/K linker length (nm). (b) cAMP levels or (c) IP1 signal for β2-AR tethered to cognate 
Gs or non-cognate Gq  respectively. (d) IP1 signal for cognate α1-AR-Gq fusions. (e) cAMP levels for 
α1-AR tethered to non-cognate Gs. (b-e) Paired Student’s t-test was performed for FRET measurements 
(black) and downstream response (colored). Data are derived from at least three independent experiments, 
with at least three replicates per condition (mean ± S.E.M. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, 
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Fig. 3.6: ER/K linker length tunes basal GPCR-Gi protein downstream response in live cells. (a) 
Schematic of the GPCR-G protein fusions. Color represents cognate GPCR-G protein pair and 
corresponding downstream response (red: α2-AR, Gs, and cAMP levels; green: A1R, α2-AR, Gi, and 
cAMP inhibition). (b-e) Fusion type is indicated on the top left. FRET Ratios (525 nm/475 nm; open 
black circles, right y-axis) and basal (ligand-free) downstream response (filled colored circles, left y-axis) 
are compared to ER/K linker length (nm). (b) Percent inhibition of 1 μM forskolin induced cAMP 
production for conical Gi coupled adenosine type 1 receptor (A1R). (c) Basal cAMP levels for A1R-Gs 
fusions. (d) % cAMP inhibition for Gi fusions and (e) cAMP levels for Gs fusions to α2-AR, a 
promiscuous Gs/Gi coupled receptor 27. (b and d) Representative experiment with at least three replicates 
per condition. (c and e) Data are derived from at least three independent experiments, with at least three 
replicates per condition. (b-e) Paired Student’s t-test was performed for FRET measurements (black) and 
downstream response (colored). Data are represented as mean ± S.E.M. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 
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Fig.3.7: GPCR-Gx fusion localize to the plasma membrane.  Representative image of live HEK293 
cells expressing α2-AR-Gs fusion (see Methods for live cell microscopy). In this image 90% membrane 
localization was detected. Analysis was performed in ImageJ (NIH) using the threshold tool to select 
membrane (C; cyan outline) and internal expression (Y; yellow outline). Percent membrane expression 





Table 3.1: Pairwise student’s t-test comparison for β2-AR-Gx fusions. Mean difference is the 
difference between the means of the indicated β2-AR-Gx (x: s or q) fusions or control sensors (–). A 
significant difference between the tested fusions are represented with the following legend: *, p ≤ 0.05; 
**, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001, n.s. not significant.  
 
Gx protein comparison Mean Difference Significance Figure 
s (minus) vs. s (ISO) 0.006217 ± 0.001242 **** 
Fig. 3b 
(ΔFRET) 
q (minus) vs. q (ISO) -0.0003354 ± 0.001766 n.s. 
(–) (minus) vs. (–) (ISO) 0.001251 ± 0.001502 n.s. 
s (ΔFRET) vs. q (ΔFRET)) -0.01365 ± 0.003462 ** 
s (ΔFRET) vs. (–) (ΔFRET) -0.01083 ± 0.004473 * 
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Table 3.2: Pairwise student’s t-test comparison for α2-AR-Gx fusions. Mean difference is the 
difference between the means of the tested α2-AR-Gx (x: s, i, q) fusions or control sensors (–). Statistical 
analysis was conducted for FRET ratio for cells treated with (Epi) or without (minus) 1 mM epinephrine. 
A significant difference between the tested conditions are represented with the following legend: *, p ≤ 















Gx protein comparison Mean Difference Significance Figure 
s (minus) vs s (Epi) 0.0004172 ± 0.002901 n.s. 
Fig.3b 
(ΔFRET) 
i (minus) vs i (Epi) 0.008794 ± 0.002406 ** 
q (minus) vs q (Epi) -0.002067 ± 0.002647 n.s. 
(–) (minus) vs (–) (Epi) -0.004545 ± 0.002012 n.s. 
i (ΔFRET)  vs s (ΔFRET) 0.009633 ± 0.003834 * 
i (ΔFRET)  vs q (ΔFRET) 0.01212 ± 0.003879 * 
i (ΔFRET)  vs (–) (ΔFRET) 0.01459 ± 0.003522 ** 
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Table 3.3: Pairwise student’s t-test comparison for GPCR-Gx fusion. FRET Ratio and downstream 
response were measured for β2-AR or α1-AR fused to Gs or Gq using three different lengths ER/K 
linkers (10 nm, 20 nm, or 30 nm) in live cells. Mean difference is the difference between the means of the 
tested GPCR-Gx fusion FRET ratio or downstream response for Figure 5. A significant difference 
between the tested conditions are represented with the following legend: *, p ≤ 0.05; **, p ≤ 0.01; ***, p 
≤ 0.001; ****, p ≤ 0.0001, n.s. not significant. 
 
Fusion Assay Comparison Mean Difference ± S.E.M. Significance Figure 
β2-AR-Gs 
cAMP 
10 vs 20 nm -13787 ± 814.6 **** 
Fig. 
3.5b 
20 vs 30 nm -3937 ± 855.4 ** 
10 vs 30 nm -17724 ± 498.2 **** 
FRET 
10 vs 20 nm -0.2184 ± 0.01533 *** 
20 vs 30 nm -0.05144 ± 0.008203 ** 
10 vs 30 nm -0.2698 ± 0.01372 **** 
α1-AR-Gs 
cAMP 
10 vs 20 nm -354.3 ± 1129 n.s. 
Fig. 
3.5d 
20 vs 30 nm -1915 ± 722.3 n.s. 
10 vs 30 nm -2269 ± 1237 n.s. 
FRET 
10 vs 20 nm -0.2514 ± 0.007691 **** 
20 vs 30 nm -0.086 ± 0.005317 **** 
10 vs 30 nm -0.3374 ± 0.007925 **** 
β2-AR-Gq 
IP1 
10 vs 20 nm -0.0191 ± 0.01366 n.s. 
Fig. 
3.5c 
20 vs 30 nm -0.009514 ± 0.01777 n.s. 
10 vs 30 nm -0.02861 ± 0.01477 n.s. 
FRET 
10 vs 20 nm -0.2688 ± 0.006816 **** 
20 vs 30 nm -0.02158 ± 0.005731 *** 
10 vs 30 nm -0.2904 ± 0.006323 **** 
α1-AR-Gq 
IP1 
10 vs 20 nm -0.06594 ± 0.008062 **** 
Fig. 
3.5e 
20 vs 30 nm -0.05721 ± 0.01508 ** 
10 vs 30 nm -0.1232 ± 0.01118 **** 
FRET 
10 vs 20 nm -0.2777 ± 0.006475 **** 
20 vs 30 nm -0.02389 ± 0.005942 * 
10 vs 30 nm -0.3016 ± 0.006235 **** 
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Table 3.4: Pairwise student’s t-test comparison for GPCR-Gx fusion. FRET Ratio and downstream 
response were measured for A1R or α2-AR fused to Gs or Gi using three different lengths ER/K linkers 
(10 nm, 20 nm, or 30 nm) in live cells. Mean difference is the difference between the means of the tested 
GPCR-Gx fusion FRET ratio or downstream response for Figure 6. A significant difference between the 
tested conditions are represented with the following legend: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; 
****, p ≤ 0.0001, n.s. not significant. 
 
Fusion Assay Comparison Mean Difference ± S.E.M. Significance Figure 
A1R-Gi 
FRET 
10 vs 20 nm -0.1375 ± 0.005836 **** 
Fig. 
3.6.b 
20 vs 30 nm -0.02529 ± 0.005765 ** 
10 vs 30 nm -0.1628 ± 0.005716 **** 
cAMP 
inhibition 
10 vs 20 nm -19.25 ± 4.141 ** 
20 vs 30 nm -13.5 ± 3.41 ** 
10 vs 30 nm -32.75 ± 2.704 **** 
A1R-Gs 
FRET 
10 vs 20 nm -0.1534 ± 0.004006 **** 
Fig. 
3.6c 
20 vs 30 nm -0.04407 ± 0.002722 **** 
10 vs 30 nm -0.1975 ± 0.004183 **** 
cAMP 
10 vs 20 nm -710.9 ± 363.9 n.s. 
20 vs 30 nm 228.4 ± 310.1 n.s. 
10 vs 30 nm -482.4 ± 349.6 n.s. 
α2-AR-Gi 
FRET 
10 vs 20 nm -0.09878 ± 0.003878 **** 
Fig. 
3.6d 
20 vs 30 nm -0.01398 ± 0.00477 ** 
10 vs 30 nm -0.1128 ± 0.004693 **** 
cAMP 
inhibition 
10 vs 20 nm -25.83 ± 5.507 * 
20 vs 30 nm -21.67 ± 6.28 * 
10 vs 30 nm -47.5 ± 7.61 ** 
α2-AR-Gs 
FRET 
10 vs 20 nm -0.09769 ± 0.006366 **** 
Fig. 
3.6e 
20 vs 30 nm -0.02075 ± 0.005947 ** 
10 vs 30 nm -0.1184 ± 0.005466 **** 
cAMP 
10 vs 20 nm -11873 ± 692.8 *** 
20 vs 30 nm -6223 ± 1069 * 
10 vs 30 nm -18096 ± 948.2 **** 
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Recent studies suggest that GPCRs exist in equilibrium of conformations, where ligand binding 
stabilizes a subset of these conformations resulting in activation of one or more distinct G 
proteins and/or arrestins. While these studies support a multiplicity of GPCR conformations they 
do not directly link the observed conformations to selection of one or more downstream 
effectors. Utilizing the well-characterized interaction between the GPCR and the C-terminus of 
the Gα subunit, novel GPCR-peptide sensors probe for ligand-dependent stabilization of GPCR 
conformations that are selective for one or more G proteins. Extended works by Semack et al. 
demonstrate “hotspot” residues on the Gα C-terminus that are necessary and sufficient for 
specificity of β2-AR (Gs/Gi coupled receptor) and V1R’s (Gq coupled receptor) interaction with 
their cognate Gα C-termini.  Although, these findings demonstrate the utility of the peptide 
sensors, Gα C-terminus is only one part of the complex GPCR-G protein interface. As such, 
complementary GPCR-G protein sensors were build, which serve the dual purpose of probing 
agonist-stimulated changes in GPCR-G protein interaction while examining the downstream 
response using the same construct. Collectively, these tools can be used to dissect the complex 
network of GPCR-G protein interactions in live cells, while exploring questions of specificity of 
GPCR-G protein interaction and how non-cognate interactions influences GPCR conformational 
diversity and downstream second messenger signaling.  
 
4.2 Introduction  
G protein coupled receptors (GPCRs) can be thought of as information conduits (1, 2). They 
detect perturbations in the external cellular environment by binding to a wide range of ligands, 
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such as small molecules, neurotransmitters, peptides, and odorants (3). GPCRs communicate 
ligand-binding event to the intracellular environment, by binding to downstream heterotrimeric 
G proteins and arrestins (3). GPCR itself does not perform any catalytic functions (2). Instead, 
active GPCR conformations facilitate internal structural rearrangement of Gα’s Ras domain, 
leading to nucleotide exchange, and subsequent G protein activation (4). 
Initial studies posited that GPCRs exist in a two-state equilibrium, an inactive (R) and active 
(R*) conformations (5). Site-directed-spin labeling experiments with bovine rhodopsin 
demonstrated an outward movement of the transmembrane helix 6 (TM6) in the active 
conformation (6).  In agreement with earlier works, co-crystal structure of agonist bound β2-AR 
in complex with Gs, TM6 displayed a 14 Å outward movement with inward movements of TM3 
and TM7. These changes create a crevice at the intracellular surface of GPCR to facilitate 
binding to the C-terminus of the G protein α subunit (7). The differences in the inactive 
conformation (antagonist, or inverse agonist bound β2-AR) (8) and the agonist bound β2-AR (7) 
are consistent with the two-state model (5). Where the level of downstream activity depends on 
how ligands effect the R <-> R* equilibrium, with agonists shifting the equilibrium to the right, 
and inverse agonists shifting the equilibrium to the left (5).  
However, recent biophysical and functional studies support a multi-state model where ligand 
binding stabilizes a specific conformation or a subset of conformational states (5).  
Combinatorial approach using chemical labeling and mass spectroscopy was used to elegantly 
demonstrate ligand-specific β2-AR conformations (9). Researchers labeled cysteine and lysine 
residues with protiated (light chain, NEM-H5) and deuterated (heavy chain, NEM-D5) N-
ethylmalemide (NEM) (9). Researchers monitored conformational changes in the presence of 
different ligands as a function of time. Proteolysis and subsequent mass spectroscopy were used 
to quantitate labeling efficiency of NEM-H5 and NEM-D5 at specific residues (9). Quantitative 
analysis revealed different labeling kinetics in the presence of different ligands, suggesting a 
broad conformational landscape for β2-AR (9).  
Subtle changes in GPCR conformation in the presence of ligands were also monitored via 19F-
NMR spectroscopy (10). Researches monitored changes in NMR signal of two cytosolic 
cysteines located on transmembrane 6 (Cys265) and transmembrane 7 Cys327) (10).  To 
facilitate analysis, singly labeled receptor was used after labeling the appropriate cysteine with 
2,2,2 trifluoroethanethiol (10). Each of the ten ligands tested altered the NMR signal at the two 
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residues to unequal extent, demonstrating conformational heterogeneity for β2-AR in response to 
different ligands (10). Temperature dependence of the NMR signal in terms of line width and 
peak intensity for the agonist isoproterenol suggested a larger degree of conformational plasticity 
for the active β2-AR state (10). These findings were corroborated with a parallel 19F-NMR study, 
which also demonstrated that ligand free state exhibits distribution of two peaks with a slow 
transition between states, indicating a two state equilibrium (11). Agonist binding induced a 
redistribution of peak intensity and width, where binding to Gs protein or Gs protein mimetic 
nanobody further enhanced peak intensity and narrowed the line width suggesting that agonist 
bound β2-AR maintains significant structural heterogeneity until it binds a G protein (11).  
 
4.3 Peptide sensors provide a link between structural and functional studies.  
While these studies support a multiplicity of β2-AR conformations they do not directly link the 
observed conformations to selection of one or more downstream effectors. To bridge this gap, as 
a first step, sensors were developed in Chapter 2 by leveraging the well-documented interaction 
between GPCR and Gα C-terminal peptide (1). Studies previously established the Gα C-
terminus as one of the key determinants of specificity of GPCR-G protein interaction (12-15). 
Crystal structures of light activated metarhodopsin bound to a C-terminal transdusin peptide 
(Gαt C-terminal peptide) (16), and of agonist bound β2-AR in complex with the nucleotide 
empty Gs (7) demonstrated that the C-terminus of the Gα binds into the cytosolic core of the 7-
transmebrane bundle. As such, peptides derived from the G C terminus were used as “baits” to 
detect G protein-selective GPCR conformations (1). 
As part of sensor design, C-terminal α5 helix from a Gα subunit was tethered to the full length 
β2-AR with an ER/K α-helical linker flanked by FRET donor and acceptor (mCerulean and 
mCitrine) (1). Sensors are thought to exist in an open, extended conformation in the non-
interacting, inactive state (1). Studies show that activation of the receptor via mutagenesis or 
agonist binding, enhance the interaction with the cognate Gα’s α5 helical peptide resulting in a 
gain in FRET ratio (1). As part of sensor design 27 residues were derived from the α5 helix of 
the indicated Gα C terminus (1). One concern with the long peptide design is that an increase in 
FRET can arise from non-specific interaction of the charged or hydrophic residues with the 
tethered GPCR or the membrane. As such, short peptide sensors with 11 C-terminal residues 
were tested, which also showed a selective increase in FRET ratio for the cognate peptide (1).  
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As expected, the canonical agonist isoprotenerol enhanced the interaction between β2-AR and 
the C-terminus of Gαs (1). Interestingly, β2-AR’s inverse agonist metoprolol decreased the 
interaction between β2-AR and the C-termini of Gαs but enhanced the interaction with Gαi (1). 
Downstream assays independently verified metoprolol stimulated Gi signaling, as the cAMP 
suppression was sensitive to pertussis toxin treatment (1). As such, FRET sensor facilitates 
interpretation of the conformational states detected by spectroscopy and also complements 
established FRET-based sensors that differentially detect agonist and inverse agonist stimuli. 
Collectively, these spectroscopic studies support the emerging paradigm, which extends the 
“on/off” switch model to equilibrium of conformations with varying efficacies in activating 
distinct G proteins and/or arrestin. Ligand binding stabilizes subset of these conformations, 
resulting in a unique second messenger response (2, 5, 17).  
 
4.4 Peptide sensors provide a foothold to explore the molecular basis of specificity of 
GPCR-G protein interaction 
Additional studies arising from this work led by Semack et al. sought to explore the molecular 
basis of G protein selection following agonist stimulation (18). Initial studies by Conklin et al. in 
1993 elegantly demonstrated that the last three amino acids of the Gαi C-terminus were 
sufficient in determining G protein specificity (12). However, this mechanism was not found to 
be true for additional GPCR-G protein combinations tested in 1996 (13). Thus far, only one 
crystal structure of the GPCR-G protein complex exists (7), which greatly hinders pairwise 
comparison of multiple GPCR-G protein interfaces to dissect the molecular basis of G protein 
selection. Sensors developed as part of Chapter 2 were apt tools to explore mechanism of G 
protein selection by comparing a Gs coupled receptor to a Gq coupled receptor.  
Semack et al. expanded the findings in Chapter 2 to show that six different Class A GPCRs: two 
Gs coupled receptors (β3-AR and D1R), two Gi coupled receptors (α2-AR and CB1), and two Gq 
coupled receptors (α1-AR and V1R), exhibit enhanced binding to their cognate Gα C-terminal 
peptides following stimulation with their respective full agonists in live cells (Fig. 4.1) (18). This 
verification further strengthened the application of this technology to dissect the mechanism of G 
protein selection.  
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In agreement with the aforementioned NMR studies (10, 11), molecular dynamics simulation 
Fig. 4.1 Gα C-terminus minimally sufficient to detect cognate pathway for six Class A GPCRs – 
(a) Schematic of GPCR FRET sensor expressed at plasma membrane in dissociated, low FRET and 
associated, high FRET state. (b, c, d) Gs-coupled GPCRs (β3-adrenergic receptor; dopamine receptor 
D1), Gi-coupled GPCRs (α2-adrenergic receptor; cannabinoid receptor type 1) and Gq-coupled GPCR 
FRET sensors (α1-adrenergic receptor; vasopressin 1A receptor) tethered to no-peptide (N), s, i, or q 
peptide and test for change in FRET upon agonist stimulation. (e) GPCR selects for G protein via Gα 
C-terminus. Results are expressed as mean ± S.E. of three independent experiments performed in 
triplicate (n ≥ 3). Asterisks represent significant differencs between  the indicated peptide compared to 
no-peptide using Tukey’s Multiple comparison’s test. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, 
p ≤ 0.0001.	
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(MD) studies performed with agonist bound β2-AR and V1R demonstrated that cognate peptide  
binding decreases β2-AR and V1R conformational flexibility to stabilize a subset of 
conformations (18). MD simulation confirmed that that cognate GPCR-peptide interactions are 
energetically favorable compared to non-cognate interactions (Fig. 4.2) (18).  Structure-based 
sequence alignment of Gαs and Gαq C-termini identified residues, which could be critical for 
receptor binding (18). Follow-up mutagenesis and chimeric studies identified hotspot residues 
within the Gα C-termini (Gαs/Gαq – Q384L/L349, Q390/E355, E392/N357) that facilitate 
selective interaction between β2-AR-Gαs and V1R-Gαq (Fig. 4.3) (18). Overall, this study 
strongly highlights the collaborative strength of molecular dynamic approach and live cell 
FRET-based assay to dissect the structural basis of G protein selection.  
 
4.5 GPCR-G protein sensors modulate GPCR-G 
protein interaction in live cells 
An important caveat in the Chapter 2 and Semack et al 
studies is that Gα C-terminus is one element of the 
GPCR-G protein interface. The co-crystal structure of 
active conformation of β2-AR in a complex with a 
nucleotide empty state of Gs protein at 3.5Å resolution 
revealed an extensive interface between β2-AR and Gs 
(Fig. 1.6) (7). The interface consists of β2-AR’s 
intracellular loop 2 (ICL2) and transmembrane 5 (TM5) 
and TM6, with Gαs elements including α5 helix, αN-
β1 junction, and α4 helix. In addition, β2-AR’s ICL2 
and the E/DRY motif make long distance (9-10Å), 
charged interactions with Gαs N-terminal α5 helix (7, 
19). Therefore, to understand how GPCR-G protein 
interaction influence downstream second messenger 
response, we constructed full-length GPCR-G protein 
SPASM sensors as described in Chapter 3. 
Fig. 4.2 Binding energies (-kcal/mol) 
of β2-AR-peptide complexes with s, i, 
and q peptides compared to ΔFRET 
(1). Binding energy results are 
expressed as mean ± S.E of 5 
independent replicates of 100 ns 
simulations. ΔFRET results are 
expressed as mean ± S.E. of 3 
independent experiments of at least 3 
repeats per experiments. Table lists the 




Current approaches to visualize GPCR-G protein interaction in cells involve probing the 
interaction between individually expressed fluorescent or luminescent protein fusions using 
FRET or bioluminescence resonance energy transfer (BRET) (20-24). Therefore, insights into 
the GPCR-G protein interaction gained from these studies are limited by their dependence on the 
relative concentration and co-localization of individually expressed GPCR and G protein. 
Alternatively, direct GPCR-G protein fusions generated by tethering the N-terminus of the Gα to 
the GPCR’s C-tail with a short or no linker in between have been used to study the influence of 
tethering different G protein subunits on G protein activation and second messenger signaling 
(25, 26). Such fusions have not been used to monitor the GPCR-G protein interaction using 
resonance energy transfer approaches (23). A limitation of direct fusions is that GPCRs with 
short C-tails do not efficiently signal to the tethered G protein (27-30).  
In Chapter 3, we describe a new approach that relies on ER/K-linked fusions (31) to compare 
downstream signaling from different GPCR – G protein pairings. In contrast to previous GPCR-
G protein fusions that use a short unstructured linker (26-28, 30, 32, 33), in the absence of an 
interaction, the structured ER/K linker provides a significant spatial separation between the 
GPCR and the G protein fused to its ends. Unlike current FRET/BRET sensors that rely on the 
co-expression of labeled GPCR and G protein subunits (20-24, 34, 35), the SPASM sensors 
require the expression of a single polypeptide that provides 1:1 stoichiometry between the 
 
Fig. 4.3. Single point mutations are 
sufficient to enhance peptide binding in 
V1AR (a) ΔFRET assay for agonist-
stimulated V1AR testing single point 
mutations in q peptide (L349Q; N357E) 
and s peptide (Q384L; E392N) compared 
to WT q and s peptide, respectively. (b) 
cAMP assay for single point mutations 
(Q384L; E392N) in Gαs-tethered V1AR 
FRET sensor compared to WT or 
untransfected HEK293 (Basal). Results 
are expressed as mean ± S.E. of three 
independent experiments performed in 
triplicate. Stars represent significance of 
mutant peptides compared to WT peptide 
using Student unpaired t test. *, p ≤ 0.05; 
**, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 
0.0001.   
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exogenously expressed GPCR and G protein. Agonist stimulation provides changes in FRET 
(ΔFRET) comparable to those previously reported using co-expressed FRET/BRET pairs (20-
22). Hence, the SPASM sensors serve the dual purpose of probing agonist-stimulated changes in 
GPCR-G protein interaction while examining the downstream response using the same construct. 
 
4.6 Future directions 
Malik et al. (1) and Semack et al. (18) studies give rise to multiple exciting questions and 
directions: (i) What is the molecular basis of G protein specificity? Specifically, what set of 
residues, motifs, or ‘residue-networks’ within the GPCR, that direct G protein selection. How did 
the specificity of GPCR-G protein interaction evolve within the class A GPCR family? (ii) A 
second direction that these tools naturally lend themselves to, is exploring how ligands exert 
their effects on GPCR conformations and GPCR-Gα C-terminal peptide interaction. Many 
agonists occupy the same ligand-binding pocket within the GPCR; however, they are 
functionally distinct and are subcategorized into full agonist, partial agonist, inverse agonists, 
antagonist, and biased agonists. (iii) Lastly, understanding the role of allosteric modulators, 
which bind to the non-orthosteric site, on stabilization of GPCR conformation?  






























Fig. 4.4: Roles of cognate and non-cognate GPCR-G protein interactions in GPCR signaling. 
(Left) GCPRs (R) are thought to exists in equilibrium of G protein selective conformations. Shown is a 
strong interaction between Gs selective GPCR conformation and Gs protein resulting in robust 
downstream signaling. In contrast, abundance of Gq activating conformation yields no or low 
downstream signaling. (Middle) In comparison, effect of non-activating GPCR conformation and G 
protein are poorly understood. (Right) Lastly, in the context of a cellular environment, where multiple 
GPCR and G proteins are expressed, the effects of non-cognate GPCR-G protein interactions on G 
protein signaling remains a black box.  
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Speculating from Semack et al findings (18), in lieu of the 19F-NMR (11) and the ternary 
complex model (36, 37), these studies suggest a tantalizing idea of G proteins as allosteric 
modulators of GPCRs. The ternary complex model also supports this framework, where G 
protein binding stabilizes high affinity interaction between ligand and GPCR (36, 37). However, 
the influence of non-cognate G proteins remains unknown. In general, the focus of most GPCR 
studies is cognate GPCR and G protein interactions. However, for a given cell with random 
distribution of GPCR on the plasma membrane, the GPCR may interact with cognate and non-
cognate G proteins alike. One interesting avenue to explore with the tools developed here is how 
non-cognate G proteins influences GPCR conformational heterogeneity and G protein selection 
(Fig 4.4). 
 
4.7 Caveats and final remarks 
FRET and functional studies performed in this work were conducted in live cells, where 
the GPCR, GPCR interaction with the tethered peptide or G protein, and the tethered G protein 
are all under regulation by the endogenous GPCR-G protein signaling machinery (1, 18). In 
addition, cellular expression levels, the relative concentration of GPCR and G protein, and the 
arrangement of these molecules on the plasma membrane may influence FRET ratio, changes in 
FRET ratio, and the extent of the downstream response. Live cell studies using these sensors 
should be done in parallel systems to understand if and how the response varies in different 
cellular contexts. Parallel approaches using these sensors and conventional techniques should be 
undertaken to facilitate interpretation of collected observations.  
The work presented here exploits the unique features of the ER/K linker to advance our 
understanding of the GPCR-G protein interaction. This thesis has extensively characterized and 
developed novel peptide and G protein sensors of GPCRs. Peptide sensors were used to explore 
the molecular basis of G protein selection and activation (1, 18, 38) . G protein sensors enabled 
dissection of a complex interconnected GPCR network in live cells. Sensors made as part of this 
study are also available through Addgene. Together, this study serves as a blueprint to dissect 
protein interactions that drive the GPCR signaling cascade. This thesis developed a systematic, 
quantitative approach to probe the multiplicity of GPCR-G protein pairings and its consequences 




The study presented in Section 4.2 exploring the molecular mechanism of G protein selection 
was a collaborative effort between graduate student Manbir Sandhu from Nagarajan Vaidehi’s 
lab at the Department of Molecular Immunology, Beckman Research Institute of the City of 
Hope and research assistant Ansley Semack and myself in our advisor’s Sivaraj 
Sivaramakrishnan’s lab. This study included molecular dynamics studies performed in the 
Vaidehi lab and the GPCR-Gα C-terminal peptide FRET sensors developed in our group as part 
of this thesis’s work. This study was conducted and lead by it’s co-authors Semack and Sandhu. 
Semack, Sandhu, Vaidehi, and Sivaramakrishnan planned, designed and analyzed results from 
experiments and jointly wrote the manuscript. My own role was in a more peripheral capacity. I 
collected the preliminary observations that were later verified and expanded upon by Semack 
and Sandhu. The study titled “Structural elements in the Gαs and Gαq C-termini that mediate 
selective GPCR signaling’ was published in the Journal of Biological Chemistry on June 21, 
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G protein-selective GPCR conformations measured using FRET 
sensors in a live cell suspension fluorometer assay 
 
Ansley Semack, Rabia U. Malik, and Sivaraj Sivaramakrishnan* 
(Manuscript modified from J Vis Exp). 
 
A1.1 Abstract 
Fӧrster resonance energy transfer (FRET)-based studies have become increasingly 
common in the investigation of GPCR signaling. Our research group developed an intra-
molecular FRET sensor to detect the interaction between Gα subunits and GPCRs in live cells 
following agonist stimulation. Here, we detail the protocol for detecting changes in FRET 
between the β2-adrenergic receptor and the Gαs c-terminus peptide upon treatment with 100 μM 
isoproterenol hydrochloride as previously characterized1. Our FRET sensor is a single 
polypeptide consisting serially of a full-length GPCR, a FRET acceptor fluorophore (mCitrine), 
an ER/K SPASM (systematic protein affinity strength modulation) linker, a FRET donor 
fluorophore (mCerulean), and a Gα c-terminal peptide. This protocol will detail cell preparation, 
transfection conditions, equipment setup, assay execution, and data analysis. This experimental 
design detects small changes in FRET indicative of protein-protein interactions, and can also be 
used to compare the strength of interaction across ligands and GPCR-G protein pairings. To 
enhance the signal-to-noise in our measurements, this protocol requires heightened precision in 
all steps, and is presented here to enable reproducible execution. 
 
A1.2. Introduction 
G-protein-coupled receptors (GPCRs) are seven-transmembrane receptors. The human 
genome alone contains approximately 800 genes coding for GPCRs, which are activated by a 
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variety of ligands including light, odorants, hormones, peptides, drugs and other small 
molecules. Nearly 30% of all pharmaceuticals currently on the market target GPCRs because 
they play a large role in many disease states2. Despite decades of extensive work done on this 
receptor family, there remain significant outstanding questions in the field, particularly with 
regards to the molecular mechanisms that drive GPCR-effector interactions. To date, only one 
high-resolution crystal structure has been published, providing insight into the interaction 
between the β2-adrenergic receptor (β2-AR) and the Gs protein3. Together with extensive 
research in the last three decades, it reiterates one specific structural component that is critical in 
this interaction: the Gα subunit c-terminus. This structure is important for both G protein 
activation by the GPCR4 and G protein selection5-6. Hence, the Gα c-terminus provides a crucial 
link between ligand stimulation of the GPCR and selective G protein activation. 
 
Research over the last decade suggests that GPCRs populate a broad conformational 
landscape, with ligand-binding stabilizing subsets of GPCR conformations. While several 
techniques, including crystallography, NMR and fluorescence spectroscopy, and mass 
spectrometry are available to examine the GPCR conformational landscape, there is a paucity of 
approaches to elucidate their functional significance in effector selection7.Here, we outline a 
Fӧrster resonance energy transfer (FRET)-based approach to detect G protein-selective GPCR 
conformations. FRET relies on the proximity and parallel orientation of two fluorophores with 
overlapping emission (donor) and excitation (acceptor) spectra8. As the donor and acceptor 
fluorophores come closer together as a result of either conformational change in the protein or a 
protein-protein interaction, the FRET between them increases, and can be measured using a 
range of methods8. FRET-based biosensors have been employed extensively in the GPCR field9. 
They have been used to probe conformation changes in the GPCR by inserting donor and 
acceptor in the third intracellular loop and GPCR c-terminus; sensors have been designed to 
probe GPCR and effector interactions by separately labeling the GPCR and effector (G protein 
subunits/arrestins) with a FRET pair10; some sensors also detect conformational changes in the G 
protein11. These biosensors have enabled the field to ask a multitude of outstanding questions 
including conformational changes in the GPCR and effector, GPCR-effector interaction kinetics, 
and allosteric ligands12. Our group was particularly interested in creating a biosensor that could 
detect G protein-specific GPCR conformations under agonist-driven conditions. This biosensor 
	 86 
relies on a recently developed technology named SPASM (systematic protein affinity strength 
modulation)13. SPASM involves tethering interacting protein domains using an ER/K linker, 
which controls their effective concentrations. Flanking the linker with a FRET pair of 
fluorophores creates a tool which can report the state of the interaction between proteins12. 
Previously1 the SPASM module was used to tether the Gα c-terminus to a GPCR and monitor 
their interactions with FRET fluorophores, mCitrine (referred to in this protocol by its commonly 
known variant, Yellow Fluorescent Protein (YFP), excitation/emission peak at 490/525 nm) and 
mCerulean (referred to in this protocol by its commonly known variant Cyan Fluorescent Protein 
(CFP), excitation/emission peak 430/475 nm). From N- to C-terminus, this genetically encoded 
single polypeptide contains: a full length GPCR, FRET acceptor (mCitrine/YFP), 10 nm ER/K 
linker, FRET donor (mCerulean/CFP), and the Gα c-terminus peptide. In this study, sensors are 
abbreviated as GPCR-linker length-Gα peptide. All components are separated by an unstructured 
(Gly-Ser-Gly)4 linker which enables free rotation of each domain. The detailed characterization 
of such sensors was previously performed using two prototypical GPCRs: β2-AR and opsin1.  
 
This sensor is transiently transfected into HEK-293T cells and fluorometer-based live cell 
experiments measure fluorescence spectra of the FRET pair in arbitrary units of counts per 
second (CPS) in the presence or absence of ligand. These measurements are used to calculate a 
FRET ratio between the fluorophores (YFPmax/CFPmax). A change in FRET (ΔFRET) is then 
calculated by subtracting the average FRET ratio of untreated samples from the FRET ratio of 
ligand treated samples. ΔFRET can be compared across constructs (β2-AR-10 nm-Gαs peptide 
versus β2-AR-10 nm-no peptide). Here, we detail the protocol to express these sensors in live 
HEK-293T cells, monitor their expression, and the setup, execution, and analysis of the 
fluorometer-based live cell FRET measurement for untreated versus drug treated conditions. 
While this protocol is specific for the β2-AR-10 nm-Gαs peptide sensor treated with 100 µM 




1. DNA preparation 
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1.1. Design sensor constructs using a modular cloning scheme. Please reference the β2-AR 
sensor design detailed previously1.   
 
1.2. Prepare DNA according to commercial miniprep kit protocol and elute in 2 mM Tris-HCl 
solution, pH 8, at concentration ≥750 ng/μL, A260/A280 of 1.7-1.9, A260/A230 of 2.0-2.29.  
 
 
2. Cell culture preparation 
 
2.1. Culture HEK-293T-Flp-n cells in DMEM containing 4.5 g/L D-glucose, supplemented 
with 10% FBS (heat inactivated) (v/v), 1% L-glutamine supplement, 20 mM HEPES, pH 
7.5 at 37 °C in humidified atmosphere at 5% CO2. Handle cells in biological safety hood 
for subsequent steps.  
 
2.2. Allow cells to grow to a confluent monolayer before passaging into six-well dishes. Time 
to achieve confluency depends on initial plating density. Use plates that come to 
confluency within 1-2 days of plating for six-well plating. A confluent 10 cm tissue 
culture-treated dish has cell density of approximately 4 x 106 cells/mL. See Figure A1.1 for 
image of cell culture growth. 
 
2.3. Wash cells with 10 mL PBS, trypsinize with 0.25% trypsin (see Discussion, paragraph 2). 
Plate 8 x 105 cells/well in 2 mL of media in tissue culture-treated six well dishes and allow 
to adhere for 16-20 hr. 
 
3. Transfection conditions 
 
3.1. Stagger transfections for constructs that may require different amounts of time to achieve 
optimal expression (between 20-36 hr). Synchronize conditions for a unified experiment 
time. Also have an untransfected control well at equivalent cell density to be used for 
background noise and scattering subtraction during analysis.  
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3.2. Bring transfection reagents to room temperature: reduced serum media, DNA, transfection 
reagent. 
 
3.3. In a biological safety hood combine reagents in a sterile microcentrifuge tube in the 
following order: mix 2 μg DNA with 100 μL reduced serum media. Spike 6 μL of 
transfection reagent into media/DNA mix without touching surface of mixture or the side 
of the tube. Set up one transfection reaction per well. Transfection conditions can be 
optimized (1-4 μg of DNA, 3-6 μL of transfection reagent) to achieve consistent expression 
levels. See Table A1.1 for more optimized ratios.  
 
3.4. Incubate mixture at room temperature in biological safety hood for 15-30 min. Do not use 
reaction if left to incubate for more than 30 min.  
 
3.5. Add reaction to cells in a drop-wise manner across well and gently shake six-well to ensure 
thorough mixing. Add one reaction per well. 
 
3.6. After 20 hr of expression, monitor fluorescence using tissue culture fluorescence 
microscope. Assess population expression with 10X objective and protein localization in a 
cell at 40X. Observe for protein expression at plasma membrane (PM). If substantial 
internalization is noted, monitor transfection until significant expression is detected at PM.  
 
4. Reagent and equipment preparation 
 
4.1. Prepare 100 mM drug stocks and store at -80 °C: isoproterenol bitartrate (100 mM in dH2O 
containing 300 mM ascorbic acid). Make on ice/in cold room, and flash-freeze 
immediately. Aliquots can be made and used up to one year.  
 
4.2. Prepare Cell Buffer (~ 2 mL/condition) and store in a 37 °C water bath. Make fresh each 
day. Reference Table 2 for Cell Buffer constituents.  
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4.3. Prepare Drug Buffer (10 mL) and store at room temperature. Reference Table A1.2 for 
Drug Buffer constituents. 
 
4.4. Acid wash cuvettes using concentrated HCl. Neutralize with a weak base (1 M KOH), and 
thoroughly wash cuvettes with dH2O. 
 
4.5. Prepare work station around fluorometer with several boxes of 10, 200, and 1000 μL pipet 
tips, a timer set with a 10 minute countdown, an accessible vacuum line with tips for 
cuvette cleaning, delicate task wipes, and squirt bottle with ultrapure H2O.  
 
4.6. Heat external water bath for fluorometer and heat block to 37 °C. 
 
4.7. Turn on fluorometer; set fluorescence collection program for CFP collection to excitation 
430 nm, bandpass 8 nm; emission range 450 nm – 600 nm, bandpass 4 nm. For YFP 
collection only as sensor control (see Discussion) set excitation to 490 nm, bandpass 8 nm, 
emission range 500 – 600 nm, bandpass 4 nm. CFP collection settings will be used to 
acquire a FRET spectrum in this experiment. 
 
4.8. Place twelve (12) 1.5 mL microcentrifuge tubes in heat block as shown in Figure A1.2 
below. These tubes are holders for cell aliquot tubes (500 μL microcentrifuge tubes.) Place 
a small piece of tissue in holders 1 and 7 to cushion the cuvettes placed here.  
 
Note: Use separate cuvettes for untreated condition and drug condition to prevent cross-
contamination.  
 
4.9. Fill holders 2-6 and 8-12 with ~750 μL of water to create a mini 37 °C water bath.  
 
4.10. Place ten (10) 500 μL microcentrifuge tubes for cell aliquots into mini-water baths 




4.11. Monitor cells for expression (see step 3.6). 
 
5. Experiment & Data Collection 
 
5.1. Reference Figure 3 for experimental schematic. When cells are ready to be harvested, 
based on protein expression detected with fluorescence microscope (see Discussion, 
paragraph 4): in biological safety hood, gently remove ~1 mL of media, resuspend cells in 
their culture with a P1000 and transfer resuspension into a 1.5 mL microcentrifuge tube.  
 
Note: Avoid using trypsin as it may digest the N-terminus and/or binding pocket of the GPCR 
sensor. 
 
5.2. Count cells to ensure proper cell density in resuspension. Optimize resuspension volume 
for 4 x 106 cells/mL.   
 
5.3. Spin cells in swinging bucket centrifuge at room temperature, 290 x g for 3 min. Remove 
supernatant after spin.  
 
5.4. GENTLY resuspend cells in 1 mL Cell Buffer (stored at 37 °C) and repeat step 5.3. 
During second spin, gather 100 mM drug stock aliquot from -80 °C; make 1:100 dilution 
in Drug Buffer for 1 mM working stock and keep at room temperature.  
 
5.5. After second spin, remove supernatant and gently resuspend cells in 1 mL of Cell Buffer 
(4 x 106 cells/mL). Measure OD600 of the samplein spectrophotometer using 1 mL of cells 
and 1 mL of Cell Buffer as blank. Cells are briefly dispensed in disposable plastic cuvette 
and transferred back to a microcentrifuge tube immediately following spec. 
 
5.6. For a control untransfected cell condition spectrum: gently resuspend untransfected cells 
in 1 mL Cell Buffer with P1000 pipet, add 90 μL of cells to cuvette and acquire FRET 
spectrum at excitation 430 nm, bandpass 8 nm, emission 450 – 600 nm, bandpass 4 nm. 
Collect 3-5 repeat spectra with fresh 90 µL of cells. Keep stock of cells at 37 °C between 
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specs, resuspend gently with P1000 between each sample aliquot, and rinse cuvette with 
ultrapure H2O between samples. 
 
5.7. For experimental conditions: aliquot 90 μL of transfected cells to each of the 500 μL tubes 
in holders 2-6, 8-12 in the heat block. Gently resuspend stock of cells with P1000 pipet 
between each aliquot. 
 
5.8. After cells are aliquoted, add 10 μL of Drug Buffer to tubes 2-6 for untreated condition 
samples.  
 
5.9. Begin experiment by adding 10 μL of 1 mM drug solution into tube 8, start the timer to 
countdown from 10 min, and gently mix tube with P200 pipet. Close tube and return to 37 
°C heat block.  
 
5.10. Immediately pick up tube 2, mix gently with P200 (use new tip), add 90 μL of cell 
suspension to untreated condition cuvette, and place in fluorometer.  
 
5.11. Acquire FRET spectrum at excitation 430 nm, bandpass 8 nm, emission 450 – 600 nm, 
bandpass 4 nm.  
 
5.12. At 9 min-10 sec, spike tube 9 with 10 μL of 1 mM drug solution, gently mix with a P200 
(use new tip), and return tube to heat block. 
 
5.13. Repeat steps 5.10-5.11 with tube 3 and 5.12 with tube 10.  
 
5.14. Repeat steps 5.10-5.13 at 1 minute intervals (08:10, 07:10, etc.) until spectra are collected 
for all untreated condition samples, and drug has been added to all drug condition samples. 
Use a fresh tip for each pipet step to prevent cross-contamination. 
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5.15. At 5 min-10 sec, begin mixing tube 8 (drug condition) gently with P200 pipet, add 90 μL of 
cell suspension to separate cuvette for drug treated sample and place in fluorometer. 
 
5.16. Acquire FRET spectrum (see step 5.11 for settings.) 
 
5.17. Repeat steps 5.15-5.16 at 1 minute intervals (04:10, 03:10, etc.) for remaining drug 
condition samples (tubes 9-12).  
 
5.18. After experiment ends, save project files, thoroughly wash cuvettes with ultrapure H2O, 
and re-stock tubes for next condition. Note: Take care to prevent cross-contamination in the 
wash step. Change the tip on the H2O bottle as well as on the vacuum line in between 
washes.  
 
6. Data analysis 
 
6.1. Save and export data files in SPC format to be used for analysis. Analysis programs are 
available for download from the Sivaramakrishnan Lab publication website (upon 
publication.)* 
 
6.2. Create path files for analysis software which include the analysis programs (v9, v15), 
untransfected samples files (see step 5.6 for untransfected cell spectrum collection), 
OUTPUT data file, and comma separated values (CSV) files for data entry.  
 
6.2.1. Enter following information into CSV file (see sample in Table A1.3) and designate 
respective conditions for each sample, including: 
File name –individual SPC graph files  
Receptor – designate which GPCR construct was tested (e.g. Β2) 
Binder – designate which peptide variant of the construct was tested (e.g. S) 
Agonist – designate untreated (N) or drug treated (D) conditions 
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Directory – the path folder in which SPC files are saved, usually organized by date 
OD – recorded optical density of sample from spectrophotometer 
  
6.3. Enter file names for untransfected samples (step 5.6) to subtract buffer and scattering 
noise from samples. 
 
6.4. Enter conditions into analysis program. 
 
6.5. Run programs to analyze samples within individual conditions (v9) and across conditions 
(v15). 
 
6.6. Exclude sample files which are apparent outliers in the data set, or adjust for subtraction 
by increasing or decreasing OD value of individual files.  
 
6.7. Export data to OUTPUT file for access to calculated FRET ratios (525 nm/475 nm).  
 
6.8. Calculate ΔFRET by subtracting the average FRET ratio for untreated condition from the 
individual FRET ratios for treated (drug) conditions.  
 
A1.4. Representative Results: 
 
A generalized schematic of the experiment set up and execution is detailed in Figure 
A1.3. In order to detect a FRET change in the narrow dynamic range of the sensor, it is critical 
that the nuances of the system be adhered to. Cell quality is imperative to protein expression as 
well as consistency in sampling. Figure A1.1 features images of cultured cells growing in a 
consistent monolayer (10X) that is optimal for six-well plating and transfection Figure A1.1 (a) 
and cells growing in clumped patterns that lead to dendritic shapes Figure A1.1 (b) which is not 
recommended for consistent plating. Transfection conditions can also be optimized in order to 
achieve reproducible expression. Several conditions have been optimized for the recommended 
transfection reagent used here. Table A1.1 details these conditions for reduced serum media. 
DNA, and transfection reagent ratios.  
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Once all data has been collected and data entered into the CSV file for analysis (see 
sample in Table A1.3), the generated results will resemble the Raw FRET spectra data shown in 
Figure A1.4 (a) and the normalized, mean FRET spectra shown in Figure A1.4 (b). In Figure 
A1.4 the red spectra are the untreated samples and the blue are the drug treated samples. All of 
the Raw FRET spectra in Figure A1.4 (a) have sufficient signal-to-noise range for consistent 
data analysis (i.e. CPS at 450 nm compared to CPS at 475 nm). With this range, the spectra is 
smoother and the water peak from the sample (Raman peak is at 500 nm) is also minimal. Low 
expression levels result in a prominent water peak that interferes with data analysis. Data is 
normalized at 475 nm, setting the CPS of this value to 1.0 Figure A1.4 (b). In this data set for 
the β2-AR-10 nm-Gαs peptide sensor, there is a significant change at the 525 nm reading 
between untreated (red) and treated (blue) samples. The ΔFRET change is calculated from the 
FRET ratios (525 nm/475 nm) of these data sets and are accessible through the OUTPUT file. 
If protein expression is low, there is poor transfection efficiency, or low cell density in 
the cuvette for fluorescence reading, spectra may appear noisier, as shown in Figure A1.5. 
Compared to Figure A1.4 (a) the signal-to-noise range for this data set is not ideal, at 
approximately 1.0-1.6, with CPSmax of 4 x 105. This low expression level contributes to the jagged 
spectra seen in the raw data Figure A1.5 (a), however the data is tight and able to be normalized 
Figure A1.5 (b). Though the water peaks (~500 nm) does not line up completely between data 
sets Figure A1.5 (b) this experiment is still usable for analysis. Figure A1.6 is representative of 
an experiment that is inadequate for analysis. While the signal-to-noise of the sample is 
approximately 2-3 for treated (blue) and untreated (red) samples, cell density in the cuvette 
across samples is too low (450 nm value of 1x105) Figure A1.6 (a). This creates an issue in 
background subtraction and normalization Figure A1.6 (b) and the spectra do not align. 
Subtraction can be adjusted for samples by increasing or decreasing OD in Table A1.3. 
However, even with low cell density, the water peak (~500 nm) becomes much larger and noisier 
Figure A1.6 (c) and inhibits this data set from further analysis.  
 
A1.5. Discussion: 
The tight dynamic range of FRET measurements in this system reinforces the necessity of 
sensitive quality control in every step of this protocol. The most important steps to ensure a 
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successful FRET experiment are 1) cell culturing, 2) transfection 3) protein expression and 4) 
timely, precise coordination during the assay execution.  
 
Cell health and maintenance/plating quality can have a significant impact on the signal-to-noise 
of the experimental system and poor cell health can make it impossible to detect any consistent 
change in FRET. Conservatively, cells are healthiest for approximately 20 passages, though this 
may vary based on cell line, handling, and culture conditions. Once cells have difficulty growing 
as a confluent monolayer, or begin growing consistently in more dendritic patterns (see Figure 
A1.1 (b)), experimental background noise will be adversely affected. Careful cell maintenance, 
including routine media changes and regularly removing non-adherent cells and debris from 
maintenance plates, will enhance the quality of cells for six-well plating and transfections. Cell 
clumps, which adversely affect transfection efficiency, can be effectively separated into 
individual cells by trypsinization of maintenance plates: treat 10 cm confluent dishes with 10 mL 
of 0.25% trypsin for 30 seconds, remove trypsin but leave approximately 200 μL, place dish in 
37 °C incubator for 2-3 minutes. Cells will come off dish very easily and are less susceptible to 
clumping. 
 
It is critical to optimize the transfection step for this experiment. Six-wells must ideally be 60-
80% confluent for efficient transfection and optimal expression. If too few cells have adhered 
(<60%), wait approximately 2-6 hours to transfect, or until at least 70% of cells are adhered. Six-
wells that are over-confluent (> 80%) will also reduce transfection efficiency. Transfecting at 
lower cell confluency increases cell death rate.  DNA concentration and purity are also critical 
(see Step 1.2.) Using low concentration and/or poor quality DNA preparations negatively affect 
transfection efficiency Transfection conditions can be adjusted per construct; refer to Table A1.1 
for more information.  
 
Accurate and consistent monitoring of protein expression using a tissue-culture fluorescence 
microscope is another crucial step in this process. Though this step is subject to individual 
judgement, it is possible to use other techniques, such as microscopy, to monitor expression over 
time quantitatively, though they are not detailed here. For constructs we have tested successfully 
in our system, expression takes approximately 18-36 hr to reach optimal expression. In our 
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experience, constructs that display poor expression during this time window rarely improve after 
40 hr. The constructs we have published with have not shown signs of degradation, however this 
may be an issue for some GPCRs. In our assays, sensor degradation is possible at transfection 
times over 30 hr. Sensor integrity can be tested using YFP/CFP ratios: 525 nm reading from the 
YFP-excited (490 nm) spectrum, and 475 nm reading from CFP-excited (430 nm) spectrum. For 
settings, see step 4.6. Recommended YFP/CFP ratios are in the range of 1.7-2.0, with an ideal 
ratio of 1.8. This value is dependent on the approximate two-fold greater brightness of YFP 
relative to CFP14. An integral sensor with minimal degradation will therefore contain both 
fluorophores and have YFP:CFP ratio of approximately 2:1. After sensor quality has been 
confirmed it is important to confirm protein localization and expression at the plasma membrane. 
Significant intracellular expression could be a result of either protein degradation, 
internalization, or ongoing trafficking of the protein. Monitor constructs over time to see if 
expression is enhanced at the plasma membrane. The next critical challenge in expression is 
transfection efficiency. Approximately 70%+ transfection efficiency is necessary for adequate 
signal-to-noise detection in this fluorometer system. If less cells are transfected, the amount of 
signal-to-noise may still be detectable but will be much less consistent between samples in one 
FRET experiment. This will hinder accurate data analysis within the narrow dynamic range of 
the system. Expression levels also present a significant hurdle to achieving ample signal-to-noise 
during the experiment. For expression levels detectable by the fluorometer, the ratio of signal 
between 475 nm and 450 nm (cell scattering) of 1.5 is sufficient for detecting a change in FRET, 
however optimal expression will have a ratio of approximately 2.0+. For reference, the β2-AR 
data is collected in a signal-to-noise range of 4 x 105 CPS (450 nm) to 1 x 106 CPS (475 nm), 
signal-to-noise ratio of 2.5. This ratio will help reduce the amount of variability between 
samples, which can also affect data analysis. These expression levels are also subject to the 
sensitivity and optimal alignment of the fluorometer optics; other systems may require different 
parameters for adequate signal-to-noise optimization.  
 
Cells are extremely sensitive to time and temperature; once the experimental procedure has 
begun, gentle handling is essential to avoid cell death. Specific logistical measures can be taken 
to expedite the process and avoid timely mistakes including preparing the work station, making 
sure all equipment is functioning properly, and planning out the goals of the experiment 
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beforehand. It is ideal to use cells within 30 min of harvesting, and in our system, this protocol is 
executed within 20 min. Once the technique is mastered, specifically transfection optimization 
and the manual dexterity of the exercise itself, this experiment can be used to compare various 
constructs against each other, generate dose-response curves, and the sensor can be expanded to 
the full-length G protein. 
 
Though the FRET sensor used here is a unique development in GPCR FRET sensors, this 
specific experimental setup is detailed as a well-characterized assay for the implementation of 
the sensor. The fluorometer-based assay allows a large population of cells to be assessed in each 
experiment and does not rely on purified protein or membrane preps, therefore maintaining an in 
vivo environment. This experimental design has also been optimized to detect very small changes 
seen in the system upon agonist stimulation of the GPCR.  
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A1.7 Figures and Tables: 
 
Figure A1.1. Example of cultured cell growth. Cells growing in a monolayer (a) are ideal for 
consistent plating and transfection. Cells that appear to grow in clumps or with dendritic patterns 
(b) may not plate consistently in six-wells, may display poor transfection efficiency, and may 








Figure A1.2. Microcentrifuge tube set up and position reference in heat block. Cuvette for 
untreated samples is in position 1; cell aliquot tubes are in positions 2-6. Cuvette for drug treated 













Figure A1.4. Representative data analysis for β2-AR-10 nm-Gαs peptide +/- drug. 
Representative image of raw data (a) and normalized, averaged data (b) collected with the β2-
AR-10 nm-Gαs peptide sensor with untreated (red) samples and treated (blue) samples after 5 
minute incubation with 100 uM isoproterenol bitartrate. CFPmax emission at 475 nm, YFPmax 





























450 500 550 600
Wavelength (nm)


























Figure A1.5. Analysis of poor protein expression with raw and normalized data. Noisy raw data 
spectra (a) are a result of low expression levels, low cell density per sample, and/or poor 
transfection efficiency of construct. This data set is still interpretable as normalized (b), although 



















Example of poor protein expression
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Figure A1.6. Analysis of low cell density in fluorometer cuvette with raw and normalized data 
sets. The low cell density per sample, seen in raw data (a) complicates water/background 

















Example of low cell loading
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Table A1.1 ∆FRET transfection conditions. This table includes the optimized conditions of 
reagents for transfections into 2 mL wells of HEK-293T cells using the recommended 
transfection reagent.  
 
Condition 0.5x 0.7x 1x 2x 2x* 
DNA 1 μg 1.4  μg 2  μg 4  μg 4  μg 
Reduced serum media 100  μL 70  μL 100  μL 100  μL 200  μL 
Transfection reagent 3  μL 4.2  μL 6  μL 6  μL 12  μL 
 
*Note: Recommended for exceptionally difficult construct. Caution must be taken, as this 
condition induces high cell death.  
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Table A1.2. Live cell ∆FRET buffer constituents. This table details the reagents used to make 
both Cell Buffer and Drug Buffer for use in the experiment. Make both buffers fresh each day of 




   Volume Reagent Comments 
9 mL ultrapure DNase/RNase free water   
1 mL HBS (10X), pH 7.4, store at 4 °C:   
  200 mM HEPES   
  50 mM KCl   
  450 mM NaCl   
  20 mM CaCl2- H2O   
  10 mM MgCl2 - H2O   
100 μL  20% D-glucose   
15 μL aprotinin (1 mg/mL in dH2O)  prevents degradation 
15 μL leupeptin (1 mg/mL in dH2O) prevents degradation 
100 μL  ascorbic acid (100 mM in dH2O)* stabilizes agonist 
  *add immediately before beginning assay   
   
   Drug Buffer 
 
   Volume Reagent Comments 
9 mL ultrapure DNase/RNase free water   
1 mL HBS (10X), pH 7.4, store at 4 °C:   
  200 mM HEPES   
  50 mM KCl   
  450 mM NaCl   
  20 mM CaCl2- H2O   
  10 mM MgCl2 - H2O   
100 μL  ascorbic acid (100 mM in dH2O)* stabilizes agonist 







Table A1.3. Sample CSV file for ∆FRET experiment analysis. This sample data file highlights 
the entry set after one experiment. Multiple experiments can be entered into the same CSV file 
and can be discerned under the ‘Additive’ column if necessary. Each row must be filled out with 
the following information: 
File name – individual SPC graph files 
Receptor – designate which GPCR construct was tested (e.g. Β2) 
Binder – designate which peptide variant of the construct was tested (e.g. S) 
Agonist – designate untreated (N) or drug treated (D) conditions 
Directory – the path folder in which SPC files are saved, usually organized by date 























UN N N N C N FRET 20160101 0.8 
B2AR s pep minus 
(01)_Graph.SPC B2 10 S N C N FRET 20160101 0.4 
B2AR s pep minus 
(02)_Graph.SPC B2 10 S N C N FRET 20160101 0.4 
B2AR s pep minus 
(03)_Graph.SPC B2 10 S N C N FRET 20160101 0.4 
B2AR s pep minus 
(04)_Graph.SPC B2 10 S N C N FRET 20160101 0.4 
B2AR s pep minus 
(05)_Graph.SPC B2 10 S N C N FRET 20160101 0.4 
B2AR s pep drug 
(01)_Graph.SPC B2 10 S D C N FRET 20160101 0.4 
B2AR s pep drug 
(02)_Graph.SPC B2 10 S D C N FRET 20160101 0.4 
B2AR s pep drug 
(03)_Graph.SPC B2 10 S D C N FRET 20160101 0.4 
B2AR s pep drug 
(04)_Graph.SPC B2 10 S D C N FRET 20160101 0.4 
B2AR s pep drug 
(05)_Graph.SPC B2 10 S D C N FRET 20160101 0.4 
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Appendix 2 
Molecular mechanisms of G protein activation 
A2.1 Abstract 
Heterotrimeric G proteins, consisting of Gα, Gβ, and Gγ subunits, are important signaling 
molecules that play a critical role in wide range of physiological processes.  Currently, there are 
76 crystal structures of Gα in the inactive and active states, including one in nucleotide empty 
state in complex with an active G protein coupled receptor (GPCR). Despite the wealth of 
structural information, the molecular mechanism that result in G protein activation remains an 
active area of research. The studies discussed in this section explore the molecular mechanisms 
by which binding of GPCR at distal sites influences G protein’s nucleotide state. 
 
A2.2 Introduction 
Heterotrimeric G proteins are important signaling molecules as they play a critical role in wide 
range of physiological processes including cell growth, apoptosis, homeostasis, and immune 
response.  The heterotrimeric G proteins, named for their ability to bind guanine nucleotides 
(GDP and GTP) are made of α, β, and γ subunits. There are three distinct nucleotide states: (i) 
inactive GDP bound state, (ii) active GTP bound state, and (iii) transitory nucleotide empty state. 
Nucleotide state of the G protein is under tight regulation by multiple regulatory proteins.  
Principal of these regulatory proteins are Guanine nucleotide Exchange Factors (GEF’s). G 
protein coupled receptors or GPCRs function as GEF’s. GPCRs convert detection of 
extracellular stimuli into intracellular response by binding to G proteins and promoting GDP 
exchange for GTP. In this cycle, the GDP bound G protein binds to the receptor, dissociates 
GDP and transition into a nucleotide-empty state, and binds to GTP, which subsequently triggers 
functional dissociation of Gα•GTP and Gβγ subunits. The activated G protein then acts on its 
effectors to initiate production of second messenger response. The Gα’s inherent GTPase 
activity is very poor. Regulators of G protein Signaling (RGS’s) serve as GTPase Activating 
Proteins (GAP’s) by binding to Gα•GTP subunit and enhancing its catalytic activity to inactivate 
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the Gα subunit (1). Hydrolysis of the inorganic γ-phosphate converts GTP to GDP and promotes 
re-binding to Gβγ to re-initiate the G protein cycle (1) (Fig. A2.1). Guanine Dissociation 
Inhibitors (GDI’s) also regulate this cycle by sequestering the GDP-bound G protein in the 
cytosol, and thus prevent its association with membranes and subsequent activation by GPCRs. 
Thus far, there are 40 structures of Gα in the GAP interacting state, 25 in the GTP bound active 
state, 11 in the inactive GDP state, and one nucleotide empty state in complex with the activated 
β2-AR (GEF) (18). Despite the wealth of structural information, the molecular mechanism that 
result in G protein activation remains an active area of research. The studies discussed in this 
section explore the molecular mechanisms by which binding of GPCR at distal sites influences G 
protein’s nucleotide state. 
 
A2.3 Gα structure 
Considerable insight into the conformational changes in the Gα subunit has been gleamed from 
the crystal structures of G proteins in various states. The Gα subunit consists of Ras-like GTPase 
domain (RGD) and an α helical domain (HD) (2). RGD is highly conserved across the GTPase 
superfamily, and is primarily responsible for G protein’s catalytic activity (2). HD is unique to 
heterotrimeric G proteins and consists of six α helices and switch I, II, and III regions. Two 
linkers (L1 and L2) tether HD to RGD. Guanine nucleotides are thought to stabilize the 
interaction between the HD and RGD domains (2). The Gα’s switch regions show significant 
conformational differences between the GDP and GTP bound state (2). GTP’s inorganic γ-
phosphate interacts with switches I and II, and thus stabilize an active Gα conformation that 
stimulates downstream effectors (1).  In the absence of the γ-phosphate, in the GDP bound state, 
the two switches move apart from each other and lose their affinity for downstream effectors (1). 
This is one mechanism by which G proteins store and transmit information based on the 
conformational state of the Gα subunit.  
 
A2.4 Role of Gα’s domain opening in G protein activation 
In the transitory nucleotide empty state, double electron-electron resonance spectroscopy 
(DEER) (3), cryo-EM (4), and β2-AR-Gs co-crystal structure (5) confirm a dramatic domain 
separation between the Ras-like GTPase domain (RGD) and the α helical domain (HD). Studies 
suggest that the clamshell like opening of the RGD-HD is one mechanism for facilitating GDP 
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escape. Molecular dynamic simulation studies of Gi•GDP, Gi•GTP, and Gi•Rhodospin elegantly 
demonstrate that Gi displays spontaneous RGD-HD opening in the absence of GPCR – albeit at a 
very low rate (6). This phenomenon is indirectly hinted at the lack of crystal structures of this 
conformation in the absence of a receptor, as the process of crystallography captures the 
abundant energetically favorable state. Researchers further noted that the domain opening, in the 
absence of the receptor, is necessary but not sufficient for nucleotide escape (6). Under 
spontaneous separation conditions, GDP still retained strong interactions with RGD and 
relatively weaker interactions with HD. Binding of the receptor was necessary to enhance 
domain separation and decrease RGD affinity for GDP to promote nucleotide dissociation (6). 
Nevertheless, the mechanism by which GPCR promote domain opening resulting in robust 
nucleotide exchange remained unclear. 
 
A2.5 Role of Gα C-terminal α5 helix 
A range of biophysical experiments using x-ray crystallography, (5, 7), double electron-electron 
resonance spectroscopy (DEER) (3), electron microscopy (4), and hydrogen-deuterium-exchange 
mass spectroscopy (DXMS) (8) paved the way for exploring the molecular mechanism of G 
protein’s nucleotide exchange and subsequent G protein activation. These parallel studies concur 
on the critical role of the Gα’s C-terminal α5 helix in G protein activation. In the β2-AR-Gs 
complex crystal structure, α5 constitutes ~70% of the total β2-AR-Gs interface (5, 9).  
Comparing the GDP and nucleotide free state, α5 helix often adopts a conformation similar to 
the one observed in the β2-AR-Gs structure and the rhodopsin-Gi model. In this conformation, 
α5 helix moves away from the nucleotide-binding site. Repositioning of the α5 helix in these 
studies, correlate with enhanced mobility in the β6-α5 loop, which directly binds GDP (6). 
Further constraining the α5 helix in the GPCR-interacting conformation, MD simulations predict 
enhanced domain opening and nucleotide escape (6). Researchers proposed a mechanism by 
which rotation and binding of the α5 helix to the GPCR rearranges non-covalent interactions, 
resulting in mobility of the β6-α5 loop and loss of affinity of RGD for GDP, leading to domain 
separation and subsequent nucleotide exchange (6).  
Insight into how repositioning of the α5 helix influences nucleotide dissociation was gained from 
comparative structural analysis (9) and alanine mutagenesis screening studies (10). Alanine 
screening characterized residues into different clusters. Residues in the G protein-activating 
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cluster were found in α1 and α5 packed against β1- β3 strands in the nucleotide bound states 
(10). Both sets of studies concurred that in the receptor-bound state the interaction between α1 
and α5 is weakened, wherein α5 looses 20% of its Gα interacting contacts with α1 (9, 10). 
Instead, a new set of interactions is formed between α5 and β4-β6 strands. Comparative analysis 
studies suggested that α1 functions as a hub that links different functional Gα regions. In the 
nucleotide bound state, α1 makes non-covalent interactions with the N-terminus of α5 through 
conserved residues to link α5 to the GDP binding site (9). One such interaction is coordinated 
via Gαi’s residue F336 positioned at the N-terminus of α5 (9, 11). Mutagenesis of F336 perturbs 
stability of GTP and GDP bound states without altering the ability to form a complex with the 
receptor (10, 11). These studies suggest that the N-terminus of α5 forms a network of interaction 
with β2 and β3 strands and α1. Repositioning of α5 results in displacement of α5 N-terminus 
leading to re-organization of this cluster of interaction (9-11). Comparative analysis further 
posits that α1 functions as the molecular switch for GDP release, whereas the α5 helix is the 
‘distal trigger’ that is ‘pulled’ on by the receptor (9).  
Additional MD studies conducted by Yao et al. questioned how binding of GDI or GEF’s from 
sites that are distal from the nucleotide-binding pocket, influence the nucleotide state.  
To that end, reserachers characterize the structural dynamics of GDI, GDP, and GTP bound 
states (12). Principal component analysis on crystal structures of Gi-family revealed that switch 
I, II, III regions are highly flexible. Additional ensemble-based correlation network analysis, 
enabled tracking of changes in the dynamic coupling of residue pairs in Gi bound to GDP, GTP, 
or GDI states. Analysis revealed an overall ‘tightening’ or shortening of path-lengths between 
different distal functional sites within the GTP state compared to the GDP and GDI states. α5 
formed a community of interaction with β4 and β6 strands in the GDP bound state, and was 
additionally linked to β1 and β3 strands in the GTP bound state.  
Network path analysis of residues that linked (source) receptor binding site to (sink) nucleotide 
γ-phosphate binding site and domain interface, revealed additional features that distinguish GDP 
and GTP bound states.  This analysis indicated residues that were on the dominant path linking 
the source and sink regions.  Network path analysis suggested that L32-I339 were key mediators 
of GTP specific coupling between α5 and β1 strand. Whereas F195 on β3 strand was suggested 
to couple path between β1 and RGD-HD interface. Interestingly, D333 located on α5-helix is 
exposed to the solvent, but was identified to be on the path that links receptor binding to 
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nucleotide exchange. MD simulations of mutants of these residues indicated enhanced domain 
separation rates where I339A>F332A>L32A>F195L>D333A=WT (Fig. A2.2a). As noted by 
Dror et al., domain opening is necessary but not sufficient for nucleotide exchange (6). The basal 
activity of these mutants was subsequently examined in live cells. Activity of the G protein was 
examined for equivalent levels of its activating GPCR. Interestingly, D333A and L32A mutants 
robustly enhanced basal, receptor free, activity of these mutants in live cells and an enhanced 
GTPγS incorporation rate (Fig. A2.2 b-f).  In line with previous studies, Yao et al study re-
affirmed the importance of α5-helix and its interaction with the β6-α5 loop (13). It further 
highlighted an additional role of the β1 strand that directly links the receptor to the phosphate 
coordinating P-loop. 
 
A2.6 An emerging model of G protein activation 
A model encompassing these various biophysical, computational, biochemical and cellular 
studies (3-9, 11-13), suggests that the C-terminus of the α5-helix, rotates, and transitions from a 
disordered to an ordered state, as it binds the cytosolic core of the receptor. The last C-terminal 
residues of the α5-helix serve as specific site of interaction with the receptor. Post binding to 
GPCR, α5 looses previously formed interactions with the Gα subunit. The N-terminus of α5, 
which does not insert into the receptor, forms a new set of interactions that convey binding of the 
receptor to the Gα’s nucleotide binding pocket. Subsequently, interactions with the β6-α5 loop 
located at the N-terminus of α5 with β1 and β3 strand are re-arranged. Re-organization of non-
covalent interaction between these different hubs weakens the affinity of the RGD for GDP, 
resulting in domain opening, and GDP dissociation. GTP, which is present at a higher cytosolic 
concentration than GDP binds and activates the G protein. The residues that regulate nucleotide 
exchange are found on both the α5 helix (D333 and F332/F336) and on paths that link the α5-β1 
strand, which links the distal binding of the α5 to the GPCR to the Gα’s phosphate coordinating 
P-loop. The proposed model needs further verification. Biochemical and cellular studies are 
needed to test if this mechanism is universal for all G proteins. Further analysis is needed to 
determine if this mechanism holds true for additional GPCR-G protein combinations.   
A caveat to the aforementioned model is that it emphasizes the role of Gα’s C-terminal α5 helix 
in GPCR mediated nucleotide exchange, resulting in robust G protein activation. However, the 
co-crystal structure of β2-adrenergic receptor in a complex with Gs protein reveals an extensive 
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interface consisting of β2-AR’s intracellular loop 2 (ICL2), transmembrane 5 (TM5) and TM6, 
with Gαs N-terminal α-helix, and RGD elements including α5 helix, αN-β1 junction, and α4 
helix. Initial studies suggest that the Gα’s N-terminal α helix is also a key determinant of 
specificity of GPCR-G protein interaction (8). Structural and DXMS studies highlight an 
additional role of Gα N-terminus α-helix (αN) in G protein activation (5, 8), where they note 
high exchange rates for ICL2 and Gα’s α1 helix, and the β1 strand linking ICL2 of the agonist 
bound receptor to the P-loop that coordinates β-phosphate of GDP in Gαs. Together, these 
studies suggest that the GPCR engages Gα’s N-terminus and alters the position and/or the 
stability of the β1 strand with associated changes in the P-loop and the α1 helix (8). These 
finding underscore the need to explore the potential role of Gα’s N-terminus in GPCR mediated 
nucleotide exchange.  
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the Journal of Biological Chemistry on December 24, 2015 (12). This study is discussed in light 







Fig. A2.1: Schematic of the G protein 
cycle. GPCRs function as guanine 
nucleotide exchange factors (GEF’s) and 
promote nucleotide exchange from GDP 
to GTP leading to G protein activation. 
RGS function as GTPase activating 
proteins (GAP’s) to enhance catalysis of 




























































































































































































































Fig. A2.2: Computational and experimental mutagenesis of on path residues. Computational and 
experimental mutagenesis of on path residues. a, fraction of domain opening events observed 
relative to wild-type (WT) simulations for L32A, F195L, F332A, D333A and I339A. The same wild-
type simulation protocols and network analysis methods were implemented for all mutant simulations. 
Domain opening was detected whenever the minimum Cα-Cα distance between LE (on the HD side) 
and SIII (on RasD) exceeded 10Å in the cumulative 5×80ns simulations. “Control” refers to a set of 
five separately performed wild-type simulations. Note that all simulations were structurally stable as 
indicated by standard geometric analysis (data not shown). b, probability density distribution of path 
lengths from receptor coordinating β1 (K31) to RasD-HD interface (D146) in wildtype and mutants. c, 
cAMP levels for the WT and mutant A1R-Gαi fusions for indicated conditions in live HEK293 cells 
(Untransfected (UN), 10 µM forskolin (Fsk), 12.5 nM N6-cyclopentyladenosine (CPA, A1R agonist)). 
d & e, cAMP levels for HEK293 cells expressing WT or mutant mCerulean labeled Gαi, treated 
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